WO2000068692A1 - A method of detecting an analyte using semiconductor nanocrystals - Google Patents
A method of detecting an analyte using semiconductor nanocrystals Download PDFInfo
- Publication number
- WO2000068692A1 WO2000068692A1 PCT/US2000/012227 US0012227W WO0068692A1 WO 2000068692 A1 WO2000068692 A1 WO 2000068692A1 US 0012227 W US0012227 W US 0012227W WO 0068692 A1 WO0068692 A1 WO 0068692A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- semiconductor nanocrystal
- specific
- binding
- sample
- molecule
- Prior art date
Links
- 239000004054 semiconductor nanocrystal Substances 0.000 title claims abstract description 405
- 238000000034 method Methods 0.000 title claims abstract description 175
- 239000012491 analyte Substances 0.000 title claims abstract description 121
- 108020004414 DNA Proteins 0.000 claims description 125
- 230000027455 binding Effects 0.000 claims description 93
- 238000009739 binding Methods 0.000 claims description 92
- 230000009870 specific binding Effects 0.000 claims description 77
- 150000007523 nucleic acids Chemical class 0.000 claims description 72
- 102000039446 nucleic acids Human genes 0.000 claims description 60
- 108020004707 nucleic acids Proteins 0.000 claims description 60
- 230000003595 spectral effect Effects 0.000 claims description 56
- 239000007787 solid Substances 0.000 claims description 43
- 238000003199 nucleic acid amplification method Methods 0.000 claims description 42
- 230000003321 amplification Effects 0.000 claims description 41
- 108091034117 Oligonucleotide Proteins 0.000 claims description 36
- 108090000623 proteins and genes Proteins 0.000 claims description 33
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 claims description 32
- 108091032973 (ribonucleotides)n+m Proteins 0.000 claims description 32
- 238000003752 polymerase chain reaction Methods 0.000 claims description 30
- 102000053602 DNA Human genes 0.000 claims description 29
- 230000015572 biosynthetic process Effects 0.000 claims description 29
- 210000000349 chromosome Anatomy 0.000 claims description 28
- 102000004169 proteins and genes Human genes 0.000 claims description 28
- 239000012634 fragment Substances 0.000 claims description 23
- 238000000295 emission spectrum Methods 0.000 claims description 20
- 229960002685 biotin Drugs 0.000 claims description 18
- 239000011616 biotin Substances 0.000 claims description 18
- 235000020958 biotin Nutrition 0.000 claims description 16
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 16
- 238000012544 monitoring process Methods 0.000 claims description 15
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 15
- 229920001184 polypeptide Polymers 0.000 claims description 14
- 102000040430 polynucleotide Human genes 0.000 claims description 13
- 108091033319 polynucleotide Proteins 0.000 claims description 13
- 239000002157 polynucleotide Substances 0.000 claims description 13
- 108091023037 Aptamer Proteins 0.000 claims description 11
- 108010090804 Streptavidin Proteins 0.000 claims description 10
- 230000001404 mediated effect Effects 0.000 claims description 9
- 150000003384 small molecules Chemical class 0.000 claims description 7
- 230000002759 chromosomal effect Effects 0.000 claims description 5
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical group O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 claims description 5
- 150000004676 glycans Chemical class 0.000 claims description 5
- 229920001282 polysaccharide Polymers 0.000 claims description 5
- 239000005017 polysaccharide Substances 0.000 claims description 5
- 230000008859 change Effects 0.000 claims description 4
- 238000012408 PCR amplification Methods 0.000 claims 1
- 239000000126 substance Substances 0.000 abstract description 36
- 239000000523 sample Substances 0.000 description 233
- 238000003556 assay Methods 0.000 description 109
- 239000004065 semiconductor Substances 0.000 description 70
- 238000001514 detection method Methods 0.000 description 68
- 239000013615 primer Substances 0.000 description 58
- 239000002987 primer (paints) Substances 0.000 description 58
- 239000000203 mixture Substances 0.000 description 55
- 210000004027 cell Anatomy 0.000 description 53
- 230000000295 complement effect Effects 0.000 description 53
- 150000001875 compounds Chemical class 0.000 description 53
- 239000000427 antigen Substances 0.000 description 49
- 238000009396 hybridization Methods 0.000 description 49
- 108091007433 antigens Proteins 0.000 description 47
- 102000036639 antigens Human genes 0.000 description 47
- 238000006243 chemical reaction Methods 0.000 description 38
- 125000003729 nucleotide group Chemical group 0.000 description 31
- ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 30
- 239000002773 nucleotide Substances 0.000 description 30
- 239000011324 bead Substances 0.000 description 29
- 239000003153 chemical reaction reagent Substances 0.000 description 29
- 239000004005 microsphere Substances 0.000 description 27
- 239000002245 particle Substances 0.000 description 26
- 235000018102 proteins Nutrition 0.000 description 26
- 239000002159 nanocrystal Substances 0.000 description 25
- 230000005284 excitation Effects 0.000 description 23
- 239000003086 colorant Substances 0.000 description 22
- 239000000975 dye Substances 0.000 description 22
- 239000000463 material Substances 0.000 description 22
- 238000009826 distribution Methods 0.000 description 21
- 238000005406 washing Methods 0.000 description 21
- 108091028043 Nucleic acid sequence Proteins 0.000 description 20
- 239000011162 core material Substances 0.000 description 20
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 20
- 239000002953 phosphate buffered saline Substances 0.000 description 20
- 239000003446 ligand Substances 0.000 description 19
- 102000005962 receptors Human genes 0.000 description 19
- 108020003175 receptors Proteins 0.000 description 19
- 238000004458 analytical method Methods 0.000 description 16
- 230000000694 effects Effects 0.000 description 16
- 241000894007 species Species 0.000 description 16
- 210000001519 tissue Anatomy 0.000 description 16
- 239000000872 buffer Substances 0.000 description 13
- 239000003112 inhibitor Substances 0.000 description 13
- 239000002751 oligonucleotide probe Substances 0.000 description 13
- 108091093088 Amplicon Proteins 0.000 description 12
- 239000003298 DNA probe Substances 0.000 description 12
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 12
- 239000004606 Fillers/Extenders Substances 0.000 description 12
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 12
- 229940088598 enzyme Drugs 0.000 description 12
- 239000011257 shell material Substances 0.000 description 12
- 239000007790 solid phase Substances 0.000 description 12
- 239000000243 solution Substances 0.000 description 12
- 238000001228 spectrum Methods 0.000 description 12
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 11
- 102000004190 Enzymes Human genes 0.000 description 11
- 108090000790 Enzymes Proteins 0.000 description 11
- 230000008901 benefit Effects 0.000 description 11
- 229940098773 bovine serum albumin Drugs 0.000 description 11
- 229940127121 immunoconjugate Drugs 0.000 description 11
- 230000003993 interaction Effects 0.000 description 11
- 239000010410 layer Substances 0.000 description 11
- 238000000926 separation method Methods 0.000 description 11
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 10
- 108020005187 Oligonucleotide Probes Proteins 0.000 description 10
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 10
- -1 e.g. Proteins 0.000 description 10
- 238000013537 high throughput screening Methods 0.000 description 10
- 238000003018 immunoassay Methods 0.000 description 10
- 210000004940 nucleus Anatomy 0.000 description 10
- 230000008569 process Effects 0.000 description 10
- 150000003839 salts Chemical class 0.000 description 10
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 10
- UHYPYGJEEGLRJD-UHFFFAOYSA-N cadmium(2+);selenium(2-) Chemical compound [Se-2].[Cd+2] UHYPYGJEEGLRJD-UHFFFAOYSA-N 0.000 description 9
- 230000001413 cellular effect Effects 0.000 description 9
- 238000011534 incubation Methods 0.000 description 9
- 238000004020 luminiscence type Methods 0.000 description 9
- 230000003287 optical effect Effects 0.000 description 9
- 239000012071 phase Substances 0.000 description 9
- 238000002360 preparation method Methods 0.000 description 9
- 239000000047 product Substances 0.000 description 9
- 230000005855 radiation Effects 0.000 description 9
- 108060003951 Immunoglobulin Proteins 0.000 description 8
- 206010028980 Neoplasm Diseases 0.000 description 8
- 238000002820 assay format Methods 0.000 description 8
- 239000011230 binding agent Substances 0.000 description 8
- 239000012472 biological sample Substances 0.000 description 8
- 229910052739 hydrogen Inorganic materials 0.000 description 8
- 239000001257 hydrogen Substances 0.000 description 8
- 102000018358 immunoglobulin Human genes 0.000 description 8
- 125000005647 linker group Chemical group 0.000 description 8
- 108020004999 messenger RNA Proteins 0.000 description 8
- 238000010186 staining Methods 0.000 description 8
- 238000012360 testing method Methods 0.000 description 8
- 230000007704 transition Effects 0.000 description 8
- 230000031018 biological processes and functions Effects 0.000 description 7
- 239000008280 blood Substances 0.000 description 7
- 210000004369 blood Anatomy 0.000 description 7
- 239000003795 chemical substances by application Substances 0.000 description 7
- 230000002860 competitive effect Effects 0.000 description 7
- 238000006073 displacement reaction Methods 0.000 description 7
- 239000007850 fluorescent dye Substances 0.000 description 7
- 230000005764 inhibitory process Effects 0.000 description 7
- 239000011148 porous material Substances 0.000 description 7
- 230000035945 sensitivity Effects 0.000 description 7
- 239000000758 substrate Substances 0.000 description 7
- 108020003215 DNA Probes Proteins 0.000 description 6
- 238000002965 ELISA Methods 0.000 description 6
- 102000000589 Interleukin-1 Human genes 0.000 description 6
- 108020004711 Nucleic Acid Probes Proteins 0.000 description 6
- 239000003391 RNA probe Substances 0.000 description 6
- 238000010521 absorption reaction Methods 0.000 description 6
- 230000004075 alteration Effects 0.000 description 6
- 239000005546 dideoxynucleotide Substances 0.000 description 6
- 238000000684 flow cytometry Methods 0.000 description 6
- 210000004408 hybridoma Anatomy 0.000 description 6
- 230000002209 hydrophobic effect Effects 0.000 description 6
- 239000004816 latex Substances 0.000 description 6
- 229920000126 latex Polymers 0.000 description 6
- 238000004519 manufacturing process Methods 0.000 description 6
- 239000012528 membrane Substances 0.000 description 6
- 230000004048 modification Effects 0.000 description 6
- 238000012986 modification Methods 0.000 description 6
- 239000002853 nucleic acid probe Substances 0.000 description 6
- 229920000642 polymer Polymers 0.000 description 6
- 239000011541 reaction mixture Substances 0.000 description 6
- 108700028369 Alleles Proteins 0.000 description 5
- 229910004613 CdTe Inorganic materials 0.000 description 5
- 238000001712 DNA sequencing Methods 0.000 description 5
- 229920002307 Dextran Polymers 0.000 description 5
- 229910001218 Gallium arsenide Inorganic materials 0.000 description 5
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 5
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 5
- 229910000673 Indium arsenide Inorganic materials 0.000 description 5
- GPXJNWSHGFTCBW-UHFFFAOYSA-N Indium phosphide Chemical compound [In]#P GPXJNWSHGFTCBW-UHFFFAOYSA-N 0.000 description 5
- 241000699666 Mus <mouse, genus> Species 0.000 description 5
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 5
- 208000037065 Subacute sclerosing leukoencephalitis Diseases 0.000 description 5
- 206010042297 Subacute sclerosing panencephalitis Diseases 0.000 description 5
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 5
- 230000000903 blocking effect Effects 0.000 description 5
- 201000011510 cancer Diseases 0.000 description 5
- 238000010168 coupling process Methods 0.000 description 5
- 238000005859 coupling reaction Methods 0.000 description 5
- 230000002559 cytogenic effect Effects 0.000 description 5
- 230000003247 decreasing effect Effects 0.000 description 5
- 230000001419 dependent effect Effects 0.000 description 5
- 229960002086 dextran Drugs 0.000 description 5
- 238000005516 engineering process Methods 0.000 description 5
- 238000003348 filter assay Methods 0.000 description 5
- 230000003053 immunization Effects 0.000 description 5
- 239000003547 immunosorbent Substances 0.000 description 5
- 238000000338 in vitro Methods 0.000 description 5
- RPQDHPTXJYYUPQ-UHFFFAOYSA-N indium arsenide Chemical compound [In]#[As] RPQDHPTXJYYUPQ-UHFFFAOYSA-N 0.000 description 5
- 238000002372 labelling Methods 0.000 description 5
- 229910001629 magnesium chloride Inorganic materials 0.000 description 5
- 230000035772 mutation Effects 0.000 description 5
- 230000009871 nonspecific binding Effects 0.000 description 5
- 239000002096 quantum dot Substances 0.000 description 5
- 239000002464 receptor antagonist Substances 0.000 description 5
- 229940044551 receptor antagonist Drugs 0.000 description 5
- 238000011160 research Methods 0.000 description 5
- 239000011780 sodium chloride Substances 0.000 description 5
- 230000003068 static effect Effects 0.000 description 5
- 229910021653 sulphate ion Inorganic materials 0.000 description 5
- 239000000725 suspension Substances 0.000 description 5
- 238000003786 synthesis reaction Methods 0.000 description 5
- 108090001008 Avidin Proteins 0.000 description 4
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 4
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 4
- 229910005540 GaP Inorganic materials 0.000 description 4
- 108010002352 Interleukin-1 Proteins 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- 108091093037 Peptide nucleic acid Proteins 0.000 description 4
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 4
- 108020004518 RNA Probes Proteins 0.000 description 4
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 4
- 108020004682 Single-Stranded DNA Proteins 0.000 description 4
- PPBRXRYQALVLMV-UHFFFAOYSA-N Styrene Chemical compound C=CC1=CC=CC=C1 PPBRXRYQALVLMV-UHFFFAOYSA-N 0.000 description 4
- 229910007709 ZnTe Inorganic materials 0.000 description 4
- 239000002299 complementary DNA Substances 0.000 description 4
- 238000007796 conventional method Methods 0.000 description 4
- 230000008878 coupling Effects 0.000 description 4
- 239000000706 filtrate Substances 0.000 description 4
- 238000010438 heat treatment Methods 0.000 description 4
- WPYVAWXEWQSOGY-UHFFFAOYSA-N indium antimonide Chemical compound [Sb]#[In] WPYVAWXEWQSOGY-UHFFFAOYSA-N 0.000 description 4
- 238000007834 ligase chain reaction Methods 0.000 description 4
- 230000000670 limiting effect Effects 0.000 description 4
- 229910052751 metal Inorganic materials 0.000 description 4
- 239000002184 metal Substances 0.000 description 4
- 239000008188 pellet Substances 0.000 description 4
- 230000002441 reversible effect Effects 0.000 description 4
- 238000012216 screening Methods 0.000 description 4
- SBIBMFFZSBJNJF-UHFFFAOYSA-N selenium;zinc Chemical compound [Se]=[Zn] SBIBMFFZSBJNJF-UHFFFAOYSA-N 0.000 description 4
- 238000012163 sequencing technique Methods 0.000 description 4
- 210000002966 serum Anatomy 0.000 description 4
- 239000002904 solvent Substances 0.000 description 4
- ZMBHCYHQLYEYDV-UHFFFAOYSA-N trioctylphosphine oxide Chemical compound CCCCCCCCP(=O)(CCCCCCCC)CCCCCCCC ZMBHCYHQLYEYDV-UHFFFAOYSA-N 0.000 description 4
- YBNMDCCMCLUHBL-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) 4-pyren-1-ylbutanoate Chemical compound C=1C=C(C2=C34)C=CC3=CC=CC4=CC=C2C=1CCCC(=O)ON1C(=O)CCC1=O YBNMDCCMCLUHBL-UHFFFAOYSA-N 0.000 description 3
- 241000283707 Capra Species 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 3
- 239000003155 DNA primer Substances 0.000 description 3
- 102000000743 Interleukin-5 Human genes 0.000 description 3
- 108010002616 Interleukin-5 Proteins 0.000 description 3
- 102000010786 Interleukin-5 Receptors Human genes 0.000 description 3
- 108010038484 Interleukin-5 Receptors Proteins 0.000 description 3
- 229910017680 MgTe Inorganic materials 0.000 description 3
- 108091092878 Microsatellite Proteins 0.000 description 3
- 241001529936 Murinae Species 0.000 description 3
- 241000283973 Oryctolagus cuniculus Species 0.000 description 3
- 239000004793 Polystyrene Substances 0.000 description 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
- 239000002671 adjuvant Substances 0.000 description 3
- 150000001412 amines Chemical class 0.000 description 3
- 235000001014 amino acid Nutrition 0.000 description 3
- 210000003719 b-lymphocyte Anatomy 0.000 description 3
- 239000002981 blocking agent Substances 0.000 description 3
- 238000010367 cloning Methods 0.000 description 3
- 239000011248 coating agent Substances 0.000 description 3
- 238000000576 coating method Methods 0.000 description 3
- 239000000084 colloidal system Substances 0.000 description 3
- 238000004163 cytometry Methods 0.000 description 3
- SUYVUBYJARFZHO-RRKCRQDMSA-N dATP Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@H]1C[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 SUYVUBYJARFZHO-RRKCRQDMSA-N 0.000 description 3
- SUYVUBYJARFZHO-UHFFFAOYSA-N dATP Natural products C1=NC=2C(N)=NC=NC=2N1C1CC(O)C(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 SUYVUBYJARFZHO-UHFFFAOYSA-N 0.000 description 3
- HAAZLUGHYHWQIW-KVQBGUIXSA-N dGTP Chemical compound C1=NC=2C(=O)NC(N)=NC=2N1[C@H]1C[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 HAAZLUGHYHWQIW-KVQBGUIXSA-N 0.000 description 3
- 230000007423 decrease Effects 0.000 description 3
- 230000005670 electromagnetic radiation Effects 0.000 description 3
- 230000007613 environmental effect Effects 0.000 description 3
- 230000001605 fetal effect Effects 0.000 description 3
- 239000000835 fiber Substances 0.000 description 3
- 239000000499 gel Substances 0.000 description 3
- 230000014509 gene expression Effects 0.000 description 3
- 238000003384 imaging method Methods 0.000 description 3
- 238000002649 immunization Methods 0.000 description 3
- 238000007901 in situ hybridization Methods 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 238000011065 in-situ storage Methods 0.000 description 3
- 230000004807 localization Effects 0.000 description 3
- 239000011159 matrix material Substances 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- 150000002739 metals Chemical class 0.000 description 3
- 230000031864 metaphase Effects 0.000 description 3
- MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 3
- 238000002493 microarray Methods 0.000 description 3
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
- 238000007899 nucleic acid hybridization Methods 0.000 description 3
- 239000003960 organic solvent Substances 0.000 description 3
- 230000007170 pathology Effects 0.000 description 3
- 229920002223 polystyrene Polymers 0.000 description 3
- 230000002285 radioactive effect Effects 0.000 description 3
- 238000012552 review Methods 0.000 description 3
- 238000010561 standard procedure Methods 0.000 description 3
- 238000005382 thermal cycling Methods 0.000 description 3
- 238000012546 transfer Methods 0.000 description 3
- RMZAYIKUYWXQPB-UHFFFAOYSA-N trioctylphosphane Chemical compound CCCCCCCCP(CCCCCCCC)CCCCCCCC RMZAYIKUYWXQPB-UHFFFAOYSA-N 0.000 description 3
- MYRTYDVEIRVNKP-UHFFFAOYSA-N 1,2-Divinylbenzene Chemical compound C=CC1=CC=CC=C1C=C MYRTYDVEIRVNKP-UHFFFAOYSA-N 0.000 description 2
- VZSRBBMJRBPUNF-UHFFFAOYSA-N 2-(2,3-dihydro-1H-inden-2-ylamino)-N-[3-oxo-3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propyl]pyrimidine-5-carboxamide Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C(=O)NCCC(N1CC2=C(CC1)NN=N2)=O VZSRBBMJRBPUNF-UHFFFAOYSA-N 0.000 description 2
- 229920000936 Agarose Polymers 0.000 description 2
- WOVKYSAHUYNSMH-UHFFFAOYSA-N BROMODEOXYURIDINE Natural products C1C(O)C(CO)OC1N1C(=O)NC(=O)C(Br)=C1 WOVKYSAHUYNSMH-UHFFFAOYSA-N 0.000 description 2
- 229910015808 BaTe Inorganic materials 0.000 description 2
- 229910004813 CaTe Inorganic materials 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 108020004635 Complementary DNA Proteins 0.000 description 2
- 102000012410 DNA Ligases Human genes 0.000 description 2
- 108010061982 DNA Ligases Proteins 0.000 description 2
- 108010017826 DNA Polymerase I Proteins 0.000 description 2
- 102000004594 DNA Polymerase I Human genes 0.000 description 2
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 description 2
- 229910002601 GaN Inorganic materials 0.000 description 2
- 229910005542 GaSb Inorganic materials 0.000 description 2
- 108050006617 Interleukin-1 receptor Proteins 0.000 description 2
- 102000004560 Interleukin-12 Receptors Human genes 0.000 description 2
- 108010017515 Interleukin-12 Receptors Proteins 0.000 description 2
- 102000003960 Ligases Human genes 0.000 description 2
- 108090000364 Ligases Proteins 0.000 description 2
- PWHULOQIROXLJO-UHFFFAOYSA-N Manganese Chemical compound [Mn] PWHULOQIROXLJO-UHFFFAOYSA-N 0.000 description 2
- 229910019142 PO4 Inorganic materials 0.000 description 2
- 229920001213 Polysorbate 20 Polymers 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- 229910004411 SrTe Inorganic materials 0.000 description 2
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 2
- 229960004373 acetylcholine Drugs 0.000 description 2
- DZBUGLKDJFMEHC-UHFFFAOYSA-N acridine Chemical compound C1=CC=CC2=CC3=CC=CC=C3N=C21 DZBUGLKDJFMEHC-UHFFFAOYSA-N 0.000 description 2
- PYMYPHUHKUWMLA-LMVFSUKVSA-N aldehydo-D-ribose Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)C=O PYMYPHUHKUWMLA-LMVFSUKVSA-N 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 239000012736 aqueous medium Substances 0.000 description 2
- 238000003491 array Methods 0.000 description 2
- 102000023732 binding proteins Human genes 0.000 description 2
- 108091008324 binding proteins Proteins 0.000 description 2
- 238000004166 bioassay Methods 0.000 description 2
- 210000001109 blastomere Anatomy 0.000 description 2
- 238000010322 bone marrow transplantation Methods 0.000 description 2
- 229950004398 broxuridine Drugs 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 239000002131 composite material Substances 0.000 description 2
- 239000000470 constituent Substances 0.000 description 2
- RGWHQCVHVJXOKC-SHYZEUOFSA-J dCTP(4-) Chemical compound O=C1N=C(N)C=CN1[C@@H]1O[C@H](COP([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O)[C@@H](O)C1 RGWHQCVHVJXOKC-SHYZEUOFSA-J 0.000 description 2
- NHVNXKFIZYSCEB-XLPZGREQSA-N dTTP Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)C1 NHVNXKFIZYSCEB-XLPZGREQSA-N 0.000 description 2
- 239000007857 degradation product Substances 0.000 description 2
- 238000004925 denaturation Methods 0.000 description 2
- 230000036425 denaturation Effects 0.000 description 2
- 229910052805 deuterium Inorganic materials 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 238000010494 dissociation reaction Methods 0.000 description 2
- 230000005593 dissociations Effects 0.000 description 2
- JMLPVHXESHXUSV-UHFFFAOYSA-N dodecane-1,1-diamine Chemical compound CCCCCCCCCCCC(N)N JMLPVHXESHXUSV-UHFFFAOYSA-N 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 230000002068 genetic effect Effects 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 239000012510 hollow fiber Substances 0.000 description 2
- 229940088597 hormone Drugs 0.000 description 2
- 239000005556 hormone Substances 0.000 description 2
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 2
- FDGQSTZJBFJUBT-UHFFFAOYSA-N hypoxanthine Chemical compound O=C1NC=NC2=C1NC=N2 FDGQSTZJBFJUBT-UHFFFAOYSA-N 0.000 description 2
- 230000001900 immune effect Effects 0.000 description 2
- 229940072221 immunoglobulins Drugs 0.000 description 2
- 238000002991 immunohistochemical analysis Methods 0.000 description 2
- 238000007850 in situ PCR Methods 0.000 description 2
- 238000007169 ligase reaction Methods 0.000 description 2
- 229910052748 manganese Inorganic materials 0.000 description 2
- 239000011572 manganese Substances 0.000 description 2
- 230000008774 maternal effect Effects 0.000 description 2
- 230000011987 methylation Effects 0.000 description 2
- 238000007069 methylation reaction Methods 0.000 description 2
- 238000000386 microscopy Methods 0.000 description 2
- 239000003471 mutagenic agent Substances 0.000 description 2
- 231100000707 mutagenic chemical Toxicity 0.000 description 2
- 230000003505 mutagenic effect Effects 0.000 description 2
- 238000011275 oncology therapy Methods 0.000 description 2
- 238000005457 optimization Methods 0.000 description 2
- 150000002894 organic compounds Chemical class 0.000 description 2
- 239000012188 paraffin wax Substances 0.000 description 2
- 150000008298 phosphoramidates Chemical class 0.000 description 2
- 229920002401 polyacrylamide Polymers 0.000 description 2
- 229920000570 polyether Polymers 0.000 description 2
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 2
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 2
- 229920003053 polystyrene-divinylbenzene Polymers 0.000 description 2
- ZCCUUQDIBDJBTK-UHFFFAOYSA-N psoralen Chemical compound C1=C2OC(=O)C=CC2=CC2=C1OC=C2 ZCCUUQDIBDJBTK-UHFFFAOYSA-N 0.000 description 2
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 2
- 238000004153 renaturation Methods 0.000 description 2
- 238000011896 sensitive detection Methods 0.000 description 2
- 238000001179 sorption measurement Methods 0.000 description 2
- 210000004989 spleen cell Anatomy 0.000 description 2
- 235000000346 sugar Nutrition 0.000 description 2
- 230000008685 targeting Effects 0.000 description 2
- 238000007039 two-step reaction Methods 0.000 description 2
- WGFGZNVQMGCHHV-LURJTMIESA-N (2s)-2-amino-5-(2-aminoimidazol-1-yl)pentanoic acid Chemical compound OC(=O)[C@@H](N)CCCN1C=CN=C1N WGFGZNVQMGCHHV-LURJTMIESA-N 0.000 description 1
- UFBJCMHMOXMLKC-UHFFFAOYSA-N 2,4-dinitrophenol Chemical compound OC1=CC=C([N+]([O-])=O)C=C1[N+]([O-])=O UFBJCMHMOXMLKC-UHFFFAOYSA-N 0.000 description 1
- ASJSAQIRZKANQN-CRCLSJGQSA-N 2-deoxy-D-ribose Chemical compound OC[C@@H](O)[C@@H](O)CC=O ASJSAQIRZKANQN-CRCLSJGQSA-N 0.000 description 1
- WHNPOQXWAMXPTA-UHFFFAOYSA-N 3-methylbut-2-enamide Chemical compound CC(C)=CC(N)=O WHNPOQXWAMXPTA-UHFFFAOYSA-N 0.000 description 1
- VXGRJERITKFWPL-UHFFFAOYSA-N 4',5'-Dihydropsoralen Natural products C1=C2OC(=O)C=CC2=CC2=C1OCC2 VXGRJERITKFWPL-UHFFFAOYSA-N 0.000 description 1
- FWBHETKCLVMNFS-UHFFFAOYSA-N 4',6-Diamino-2-phenylindol Chemical compound C1=CC(C(=N)N)=CC=C1C1=CC2=CC=C(C(N)=N)C=C2N1 FWBHETKCLVMNFS-UHFFFAOYSA-N 0.000 description 1
- TVZGACDUOSZQKY-LBPRGKRZSA-N 4-aminofolic acid Chemical compound C1=NC2=NC(N)=NC(N)=C2N=C1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 TVZGACDUOSZQKY-LBPRGKRZSA-N 0.000 description 1
- WOVKYSAHUYNSMH-RRKCRQDMSA-N 5-bromodeoxyuridine Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(Br)=C1 WOVKYSAHUYNSMH-RRKCRQDMSA-N 0.000 description 1
- MARUHZGHZWCEQU-UHFFFAOYSA-N 5-phenyl-2h-tetrazole Chemical compound C1=CC=CC=C1C1=NNN=N1 MARUHZGHZWCEQU-UHFFFAOYSA-N 0.000 description 1
- 229930024421 Adenine Natural products 0.000 description 1
- GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 1
- 229930195730 Aflatoxin Natural products 0.000 description 1
- XWIYFDMXXLINPU-UHFFFAOYSA-N Aflatoxin G Chemical compound O=C1OCCC2=C1C(=O)OC1=C2C(OC)=CC2=C1C1C=COC1O2 XWIYFDMXXLINPU-UHFFFAOYSA-N 0.000 description 1
- 229910017115 AlSb Inorganic materials 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 206010003445 Ascites Diseases 0.000 description 1
- 102000019260 B-Cell Antigen Receptors Human genes 0.000 description 1
- 108010012919 B-Cell Antigen Receptors Proteins 0.000 description 1
- DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 1
- 108010006654 Bleomycin Proteins 0.000 description 1
- ZOXJGFHDIHLPTG-UHFFFAOYSA-N Boron Chemical compound [B] ZOXJGFHDIHLPTG-UHFFFAOYSA-N 0.000 description 1
- 229930182476 C-glycoside Natural products 0.000 description 1
- 150000000700 C-glycosides Chemical class 0.000 description 1
- QCMYYKRYFNMIEC-UHFFFAOYSA-N COP(O)=O Chemical class COP(O)=O QCMYYKRYFNMIEC-UHFFFAOYSA-N 0.000 description 1
- 241000288030 Coturnix coturnix Species 0.000 description 1
- XUIIKFGFIJCVMT-GFCCVEGCSA-N D-thyroxine Chemical compound IC1=CC(C[C@@H](N)C(O)=O)=CC(I)=C1OC1=CC(I)=C(O)C(I)=C1 XUIIKFGFIJCVMT-GFCCVEGCSA-N 0.000 description 1
- 108020001019 DNA Primers Proteins 0.000 description 1
- 230000004544 DNA amplification Effects 0.000 description 1
- 108091008102 DNA aptamers Proteins 0.000 description 1
- 239000012623 DNA damaging agent Substances 0.000 description 1
- AHCYMLUZIRLXAA-SHYZEUOFSA-N Deoxyuridine 5'-triphosphate Chemical compound O1[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)C[C@@H]1N1C(=O)NC(=O)C=C1 AHCYMLUZIRLXAA-SHYZEUOFSA-N 0.000 description 1
- SHIBSTMRCDJXLN-UHFFFAOYSA-N Digoxigenin Natural products C1CC(C2C(C3(C)CCC(O)CC3CC2)CC2O)(O)C2(C)C1C1=CC(=O)OC1 SHIBSTMRCDJXLN-UHFFFAOYSA-N 0.000 description 1
- 206010061819 Disease recurrence Diseases 0.000 description 1
- 201000010374 Down Syndrome Diseases 0.000 description 1
- 101150029707 ERBB2 gene Proteins 0.000 description 1
- 108010067770 Endopeptidase K Proteins 0.000 description 1
- 239000004593 Epoxy Substances 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- QTANTQQOYSUMLC-UHFFFAOYSA-O Ethidium cation Chemical compound C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CC)=C1C1=CC=CC=C1 QTANTQQOYSUMLC-UHFFFAOYSA-O 0.000 description 1
- 241000767593 Eulemur hybrids Species 0.000 description 1
- KRHYYFGTRYWZRS-UHFFFAOYSA-M Fluoride anion Chemical compound [F-] KRHYYFGTRYWZRS-UHFFFAOYSA-M 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 108010043121 Green Fluorescent Proteins Proteins 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- 229910004262 HgTe Inorganic materials 0.000 description 1
- UGQMRVRMYYASKQ-UHFFFAOYSA-N Hypoxanthine nucleoside Natural products OC1C(O)C(CO)OC1N1C(NC=NC2=O)=C2N=C1 UGQMRVRMYYASKQ-UHFFFAOYSA-N 0.000 description 1
- 108010058683 Immobilized Proteins Proteins 0.000 description 1
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 description 1
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 description 1
- 108010067060 Immunoglobulin Variable Region Proteins 0.000 description 1
- 102000017727 Immunoglobulin Variable Region Human genes 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 102100026018 Interleukin-1 receptor antagonist protein Human genes 0.000 description 1
- 101710144554 Interleukin-1 receptor antagonist protein Proteins 0.000 description 1
- 102100033421 Keratin, type I cytoskeletal 18 Human genes 0.000 description 1
- 102100023972 Keratin, type II cytoskeletal 8 Human genes 0.000 description 1
- 108010066327 Keratin-18 Proteins 0.000 description 1
- 108010070511 Keratin-8 Proteins 0.000 description 1
- 102000011782 Keratins Human genes 0.000 description 1
- 108010076876 Keratins Proteins 0.000 description 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- 102000018697 Membrane Proteins Human genes 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- 241000353097 Molva molva Species 0.000 description 1
- 108700005084 Multigene Family Proteins 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 101710204212 Neocarzinostatin Proteins 0.000 description 1
- 101100384865 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) cot-1 gene Proteins 0.000 description 1
- 239000000020 Nitrocellulose Substances 0.000 description 1
- 238000000636 Northern blotting Methods 0.000 description 1
- 101710163270 Nuclease Proteins 0.000 description 1
- 239000004677 Nylon Substances 0.000 description 1
- 102000015636 Oligopeptides Human genes 0.000 description 1
- 108010038807 Oligopeptides Proteins 0.000 description 1
- 102000016979 Other receptors Human genes 0.000 description 1
- 108010058846 Ovalbumin Proteins 0.000 description 1
- 241001282110 Pagrus major Species 0.000 description 1
- 108090000526 Papain Proteins 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 102000057297 Pepsin A Human genes 0.000 description 1
- 108090000284 Pepsin A Proteins 0.000 description 1
- 206010035226 Plasma cell myeloma Diseases 0.000 description 1
- 241000276498 Pollachius virens Species 0.000 description 1
- 239000004952 Polyamide Substances 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 229920000954 Polyglycolide Polymers 0.000 description 1
- 239000004642 Polyimide Substances 0.000 description 1
- 239000004721 Polyphenylene oxide Substances 0.000 description 1
- 229920000388 Polyphosphate Polymers 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 229940124158 Protease/peptidase inhibitor Drugs 0.000 description 1
- 108010076504 Protein Sorting Signals Proteins 0.000 description 1
- KDCGOANMDULRCW-UHFFFAOYSA-N Purine Natural products N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 1
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 1
- 108091008103 RNA aptamers Proteins 0.000 description 1
- 230000010799 Receptor Interactions Effects 0.000 description 1
- 108010003723 Single-Domain Antibodies Proteins 0.000 description 1
- 238000002105 Southern blotting Methods 0.000 description 1
- 206010042602 Supraventricular extrasystoles Diseases 0.000 description 1
- 108010006785 Taq Polymerase Proteins 0.000 description 1
- RYYWUUFWQRZTIU-UHFFFAOYSA-N Thiophosphoric acid Chemical class OP(O)(S)=O RYYWUUFWQRZTIU-UHFFFAOYSA-N 0.000 description 1
- 108010034949 Thyroglobulin Proteins 0.000 description 1
- 102000009843 Thyroglobulin Human genes 0.000 description 1
- 101710120037 Toxin CcdB Proteins 0.000 description 1
- 108091061763 Triple-stranded DNA Proteins 0.000 description 1
- 206010044688 Trisomy 21 Diseases 0.000 description 1
- 208000026928 Turner syndrome Diseases 0.000 description 1
- 229910052770 Uranium Inorganic materials 0.000 description 1
- LBQVQRQFDUVUCX-MJQNIGQHSA-N [[(2R,3S,4R,5R)-5-(6-aminopurin-9-yl)-4-hydroxy-3-phosphonooxyoxolan-2-yl]methoxy-hydroxyphosphoryl] [(3R)-3-hydroxy-2,2-dimethyl-4-[[3-[2-(3-methylbutylsulfanyl)ethylamino]-3-oxopropyl]amino]-4-oxobutyl] hydrogen phosphate Chemical compound O[C@@H]1[C@H](OP(O)(O)=O)[C@@H](COP(O)(=O)OP(O)(=O)OCC(C)(C)[C@@H](O)C(=O)NCCC(=O)NCCSCCC(C)C)O[C@H]1N1C2=NC=NC(N)=C2N=C1 LBQVQRQFDUVUCX-MJQNIGQHSA-N 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 230000021736 acetylation Effects 0.000 description 1
- 238000006640 acetylation reaction Methods 0.000 description 1
- OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-M acrylate group Chemical group C(C=C)(=O)[O-] NIXOWILDQLNWCW-UHFFFAOYSA-M 0.000 description 1
- 229960000643 adenine Drugs 0.000 description 1
- 230000001464 adherent effect Effects 0.000 description 1
- 238000001261 affinity purification Methods 0.000 description 1
- 239000005409 aflatoxin Substances 0.000 description 1
- 150000001299 aldehydes Chemical class 0.000 description 1
- 239000002168 alkylating agent Substances 0.000 description 1
- 239000000956 alloy Substances 0.000 description 1
- 229910045601 alloy Inorganic materials 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- 229960003896 aminopterin Drugs 0.000 description 1
- 150000003863 ammonium salts Chemical class 0.000 description 1
- 210000001776 amniocyte Anatomy 0.000 description 1
- 238000000137 annealing Methods 0.000 description 1
- 230000001088 anti-asthma Effects 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 239000000924 antiasthmatic agent Substances 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 239000003443 antiviral agent Substances 0.000 description 1
- 229940121357 antivirals Drugs 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 description 1
- XKRFYHLGVUSROY-UHFFFAOYSA-N argon Substances [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 1
- 229910052786 argon Inorganic materials 0.000 description 1
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 description 1
- IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 1
- 239000013060 biological fluid Substances 0.000 description 1
- 230000009141 biological interaction Effects 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 229960001561 bleomycin Drugs 0.000 description 1
- OYVAGSVQBOHSSS-UAPAGMARSA-O bleomycin A2 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C OYVAGSVQBOHSSS-UAPAGMARSA-O 0.000 description 1
- 230000004397 blinking Effects 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 238000006664 bond formation reaction Methods 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 229910052796 boron Inorganic materials 0.000 description 1
- 239000012888 bovine serum Substances 0.000 description 1
- 238000010804 cDNA synthesis Methods 0.000 description 1
- 229910052793 cadmium Inorganic materials 0.000 description 1
- BDOSMKKIYDKNTQ-UHFFFAOYSA-N cadmium atom Chemical compound [Cd] BDOSMKKIYDKNTQ-UHFFFAOYSA-N 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 150000004657 carbamic acid derivatives Chemical class 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 239000011203 carbon fibre reinforced carbon Substances 0.000 description 1
- 150000007942 carboxylates Chemical class 0.000 description 1
- 150000001732 carboxylic acid derivatives Chemical group 0.000 description 1
- 150000001735 carboxylic acids Chemical class 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 239000006143 cell culture medium Substances 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 210000003850 cellular structure Anatomy 0.000 description 1
- 239000004568 cement Substances 0.000 description 1
- 230000003196 chaotropic effect Effects 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 238000001311 chemical methods and process Methods 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 230000014107 chromosome localization Effects 0.000 description 1
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 1
- 229960004316 cisplatin Drugs 0.000 description 1
- 238000012875 competitive assay Methods 0.000 description 1
- 239000003636 conditioned culture medium Substances 0.000 description 1
- 230000001268 conjugating effect Effects 0.000 description 1
- 230000021615 conjugation Effects 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- 239000011258 core-shell material Substances 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000018044 dehydration Effects 0.000 description 1
- 238000006297 dehydration reaction Methods 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 229960000633 dextran sulfate Drugs 0.000 description 1
- 238000002405 diagnostic procedure Methods 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- QONQRTHLHBTMGP-UHFFFAOYSA-N digitoxigenin Natural products CC12CCC(C3(CCC(O)CC3CC3)C)C3C11OC1CC2C1=CC(=O)OC1 QONQRTHLHBTMGP-UHFFFAOYSA-N 0.000 description 1
- SHIBSTMRCDJXLN-KCZCNTNESA-N digoxigenin Chemical compound C1([C@@H]2[C@@]3([C@@](CC2)(O)[C@H]2[C@@H]([C@@]4(C)CC[C@H](O)C[C@H]4CC2)C[C@H]3O)C)=CC(=O)OC1 SHIBSTMRCDJXLN-KCZCNTNESA-N 0.000 description 1
- KPUWHANPEXNPJT-UHFFFAOYSA-N disiloxane Chemical class [SiH3]O[SiH3] KPUWHANPEXNPJT-UHFFFAOYSA-N 0.000 description 1
- NAGJZTKCGNOGPW-UHFFFAOYSA-N dithiophosphoric acid Chemical class OP(O)(S)=S NAGJZTKCGNOGPW-UHFFFAOYSA-N 0.000 description 1
- 229920001971 elastomer Polymers 0.000 description 1
- 230000005684 electric field Effects 0.000 description 1
- 230000001804 emulsifying effect Effects 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 238000005538 encapsulation Methods 0.000 description 1
- 239000005447 environmental material Substances 0.000 description 1
- 239000003344 environmental pollutant Substances 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 239000002532 enzyme inhibitor Substances 0.000 description 1
- 229940125532 enzyme inhibitor Drugs 0.000 description 1
- 125000003700 epoxy group Chemical group 0.000 description 1
- 108700020302 erbB-2 Genes Proteins 0.000 description 1
- 230000005281 excited state Effects 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 238000005562 fading Methods 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 238000000799 fluorescence microscopy Methods 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 108020001507 fusion proteins Proteins 0.000 description 1
- 102000037865 fusion proteins Human genes 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 230000013595 glycosylation Effects 0.000 description 1
- 238000006206 glycosylation reaction Methods 0.000 description 1
- 230000005283 ground state Effects 0.000 description 1
- 239000003673 groundwater Substances 0.000 description 1
- 229940094991 herring sperm dna Drugs 0.000 description 1
- 239000000833 heterodimer Substances 0.000 description 1
- 239000008241 heterogeneous mixture Substances 0.000 description 1
- 230000001744 histochemical effect Effects 0.000 description 1
- 210000003917 human chromosome Anatomy 0.000 description 1
- 229960000890 hydrocortisone Drugs 0.000 description 1
- 239000000017 hydrogel Substances 0.000 description 1
- 229920001600 hydrophobic polymer Polymers 0.000 description 1
- 150000004679 hydroxides Chemical group 0.000 description 1
- 238000005286 illumination Methods 0.000 description 1
- 230000003100 immobilizing effect Effects 0.000 description 1
- 238000010166 immunofluorescence Methods 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 238000011532 immunohistochemical staining Methods 0.000 description 1
- 238000003364 immunohistochemistry Methods 0.000 description 1
- 238000012744 immunostaining Methods 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 239000003317 industrial substance Substances 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 229910021432 inorganic complex Inorganic materials 0.000 description 1
- 150000002484 inorganic compounds Chemical class 0.000 description 1
- 229910010272 inorganic material Inorganic materials 0.000 description 1
- 239000002198 insoluble material Substances 0.000 description 1
- 230000016507 interphase Effects 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 230000002427 irreversible effect Effects 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 108010045069 keyhole-limpet hemocyanin Proteins 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000007791 liquid phase Substances 0.000 description 1
- 210000004880 lymph fluid Anatomy 0.000 description 1
- 210000001165 lymph node Anatomy 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 238000013507 mapping Methods 0.000 description 1
- 238000000691 measurement method Methods 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000009149 molecular binding Effects 0.000 description 1
- 238000000329 molecular dynamics simulation Methods 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 description 1
- 238000007837 multiplex assay Methods 0.000 description 1
- 108700024542 myc Genes Proteins 0.000 description 1
- 201000000050 myeloid neoplasm Diseases 0.000 description 1
- 230000010807 negative regulation of binding Effects 0.000 description 1
- QZGIWPZCWHMVQL-UIYAJPBUSA-N neocarzinostatin chromophore Chemical compound O1[C@H](C)[C@H](O)[C@H](O)[C@@H](NC)[C@H]1O[C@@H]1C/2=C/C#C[C@H]3O[C@@]3([C@@H]3OC(=O)OC3)C#CC\2=C[C@H]1OC(=O)C1=C(O)C=CC2=C(C)C=C(OC)C=C12 QZGIWPZCWHMVQL-UIYAJPBUSA-N 0.000 description 1
- 150000002823 nitrates Chemical class 0.000 description 1
- 229920001220 nitrocellulos Polymers 0.000 description 1
- 229920001778 nylon Polymers 0.000 description 1
- 229940124276 oligodeoxyribonucleotide Drugs 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 210000003463 organelle Anatomy 0.000 description 1
- 239000012044 organic layer Substances 0.000 description 1
- 229940092253 ovalbumin Drugs 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 239000003973 paint Substances 0.000 description 1
- 238000010422 painting Methods 0.000 description 1
- 235000019834 papain Nutrition 0.000 description 1
- 229940055729 papain Drugs 0.000 description 1
- 229940111202 pepsin Drugs 0.000 description 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 210000005105 peripheral blood lymphocyte Anatomy 0.000 description 1
- 235000021317 phosphate Nutrition 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 238000000103 photoluminescence spectrum Methods 0.000 description 1
- 231100000719 pollutant Toxicity 0.000 description 1
- 229920000729 poly(L-lysine) polymer Polymers 0.000 description 1
- 229920000747 poly(lactic acid) Polymers 0.000 description 1
- 229920000553 poly(phenylenevinylene) Polymers 0.000 description 1
- 229920002492 poly(sulfone) Polymers 0.000 description 1
- 238000002264 polyacrylamide gel electrophoresis Methods 0.000 description 1
- 229920000058 polyacrylate Polymers 0.000 description 1
- 229920002647 polyamide Polymers 0.000 description 1
- 229920000015 polydiacetylene Polymers 0.000 description 1
- 229920000647 polyepoxide Polymers 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920001721 polyimide Polymers 0.000 description 1
- 238000006116 polymerization reaction Methods 0.000 description 1
- 239000001205 polyphosphate Substances 0.000 description 1
- 235000011176 polyphosphates Nutrition 0.000 description 1
- 229920000128 polypyrrole Polymers 0.000 description 1
- 229920000123 polythiophene Polymers 0.000 description 1
- 239000004800 polyvinyl chloride Substances 0.000 description 1
- 229920000915 polyvinyl chloride Polymers 0.000 description 1
- 150000004032 porphyrins Chemical class 0.000 description 1
- 230000004481 post-translational protein modification Effects 0.000 description 1
- 230000001376 precipitating effect Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- XJMOSONTPMZWPB-UHFFFAOYSA-M propidium iodide Chemical compound [I-].[I-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CCC[N+](C)(CC)CC)=C1C1=CC=CC=C1 XJMOSONTPMZWPB-UHFFFAOYSA-M 0.000 description 1
- 238000000734 protein sequencing Methods 0.000 description 1
- 230000004850 protein–protein interaction Effects 0.000 description 1
- 230000006337 proteolytic cleavage Effects 0.000 description 1
- IGFXRKMLLMBKSA-UHFFFAOYSA-N purine Chemical compound N1=C[N]C2=NC=NC2=C1 IGFXRKMLLMBKSA-UHFFFAOYSA-N 0.000 description 1
- 230000000113 radiomimetic effect Effects 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 239000000018 receptor agonist Substances 0.000 description 1
- 229940044601 receptor agonist Drugs 0.000 description 1
- 238000010188 recombinant method Methods 0.000 description 1
- 238000006479 redox reaction Methods 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000002040 relaxant effect Effects 0.000 description 1
- 238000009877 rendering Methods 0.000 description 1
- 230000003252 repetitive effect Effects 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 108091008146 restriction endonucleases Proteins 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 229940016590 sarkosyl Drugs 0.000 description 1
- 108700004121 sarkosyl Proteins 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 238000005204 segregation Methods 0.000 description 1
- 239000006152 selective media Substances 0.000 description 1
- 150000003346 selenoethers Chemical class 0.000 description 1
- 210000000582 semen Anatomy 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- KSAVQLQVUXSOCR-UHFFFAOYSA-M sodium lauroyl sarcosinate Chemical compound [Na+].CCCCCCCCCCCC(=O)N(C)CC([O-])=O KSAVQLQVUXSOCR-UHFFFAOYSA-M 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- 239000002689 soil Substances 0.000 description 1
- 238000007614 solvation Methods 0.000 description 1
- 238000010183 spectrum analysis Methods 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 239000011550 stock solution Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 150000003871 sulfonates Chemical class 0.000 description 1
- 239000002344 surface layer Substances 0.000 description 1
- 238000006557 surface reaction Methods 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 210000001138 tear Anatomy 0.000 description 1
- 108091035539 telomere Proteins 0.000 description 1
- 102000055501 telomere Human genes 0.000 description 1
- 210000003411 telomere Anatomy 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 229940104230 thymidine Drugs 0.000 description 1
- 229960002175 thyroglobulin Drugs 0.000 description 1
- 229940034208 thyroxine Drugs 0.000 description 1
- XUIIKFGFIJCVMT-UHFFFAOYSA-N thyroxine-binding globulin Natural products IC1=CC(CC([NH3+])C([O-])=O)=CC(I)=C1OC1=CC(I)=C(O)C(I)=C1 XUIIKFGFIJCVMT-UHFFFAOYSA-N 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 108700012359 toxins Proteins 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 230000005945 translocation Effects 0.000 description 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
- 230000007306 turnover Effects 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
- 238000012800 visualization Methods 0.000 description 1
- 229910052724 xenon Inorganic materials 0.000 description 1
- FHNFHKCVQCLJFQ-UHFFFAOYSA-N xenon atom Chemical compound [Xe] FHNFHKCVQCLJFQ-UHFFFAOYSA-N 0.000 description 1
- 229950009268 zinostatin Drugs 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
- G01N33/54313—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals the carrier being characterised by its particulate form
- G01N33/54346—Nanoparticles
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y15/00—Nanotechnology for interacting, sensing or actuating, e.g. quantum dots as markers in protein assays or molecular motors
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/531—Production of immunochemical test materials
- G01N33/532—Production of labelled immunochemicals
- G01N33/533—Production of labelled immunochemicals with fluorescent label
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
- G01N33/588—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances with semiconductor nanocrystal label, e.g. quantum dots
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2458/00—Labels used in chemical analysis of biological material
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S977/00—Nanotechnology
- Y10S977/902—Specified use of nanostructure
- Y10S977/904—Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
- Y10S977/924—Specified use of nanostructure for medical, immunological, body treatment, or diagnosis using nanostructure as support of dna analysis
Definitions
- an analyte of interest in a given sample.
- immunassays such as enzyme-linked immunosorbent assays (ELISAs) are used in numerous diagnostic, research and screening applications.
- ELISAs enzyme-linked immunosorbent assays
- an ELISA detects the presence and/or concentration of an analyte in a sample using an antibody which specifically recognizes the analyte.
- An enzyme label capable of providing a detectable signal, is conjugated to the antibody.
- the analyte is either immobilized directly onto a solid support (direct-capture ELISA) or is bound to a different specific antibody which itself is immobilized on a solid support.
- FISH fluorescence in situ hybridization
- Signal amplification is yet another method for sensitive detection of nucleic acids and other receptor/ligand interactions. Direct detection of a target nucleic acid is possible by hybridization of a complementary nucleic acid probe to the target.
- Detection of the complex can be achieved by numerous means, e.g., a labeled probe or a reagent dye that specifically attaches to the target/probe complex.
- a labeled probe or a reagent dye that specifically attaches to the target/probe complex Such "direct" detection systems are often not sensitive enough to detect a target nucleic acid in a biological sample.
- One method for overcoming this limitation is to employ signal amplification.
- Each of these methods shares some or all of a set of common features. These features include: sequence specificity derived from complementary oligonucleotide hybridization or annealing; a solid support or solid phase which allows separation of specifically bound assay reagents; and a label which is used for detecting the presence or absence of the specific, intended assay interaction. Examples of assays designed to detect the sequence of a DNA sample can be found in U.S. Patents Nos.
- the "throughput" of this technique i.e., the combination of the number of candidate compounds that can be screened and the number of systems against which candidate compounds can be screened, is limited by a number of factors, including, but not limited to: only one assay can be performed per well; if conventional dye molecules are used to monitor the effect of the candidate compound, multiple excitation sources are required if multiple dye molecules are used; and as the well size becomes small (e.g., the 1536-well plate can accept about 5 ⁇ l of total assay volume), consistent dispensing of individual components into a well is difficult and the amount of signal generated by each assay is significantly decreased, scaling with the volume of the assay.
- emission spectra of a population of semiconductor nanocrystals can be manipulated to have linewidths as narrow as 25-30 nm, depending on the size distribution heterogeniety of the sample population, and lineshapes that are symmetric, gaussian or nearly gaussian with an absence of a tailing region. Accordingly, the above technology allows for detection of one, or even several, different biological or chemical moieties in a single reaction.
- the combination of tunability, narrow linewidths, and symmetric emission spectra without a tailing region provides for high resolution of multiply sized nanocrystals, e.g., populations of monodisperse semiconductor nanocrystals having multiple distinct size distributions within a system, and simultaneous detection of a variety of biological moieties.
- the invention is directed to a method where there is a plurality of target analytes and the method further comprises: (a) providing a conjugate specific for each target analyte, wherein each semiconductor nanocrystal conjugate has an emission spectrum distinct from the other semiconductor nanocrystal conjugates; and
- the above method is one where there is more than one analyte, and the method further comprises: combining with the sample a second specific-binding molecule, wherein (i) the second specific-binding molecule comprises a first member of a second binding pair, and (ii) the combining is performed under conditions that allow formation of a third complex comprising the second specific-binding molecule and the analyte, when present; removing any unbound second specific-binding molecule; combining the third complex with a second member of the second binding pair, wherein (i) the second member of the second binding pair is linked to a second semiconductor nanocrystal that has an emission spectrum distinct from the first semiconductor nanocrystal; and (ii) the combining is performed under conditions that allow formation of a fourth complex comprising the second binding pair and an analyte; and detecting the presence of the fourth complex, if present, by monitoring a second spectral emission mediated by the second semiconductor nanocrystal in the fourth complex, wherein the second emission indicates the
- Figure 3 shows the distribution of beads among three rows (A, B and C) of eight wells with differing concentrations of semiconductor nanocrystal conjugates, as described in Example 12.
- Figure 4 is a representation of results that can be obtained when semiconductor nanocrystals are used in a homogeneous scintillation inhibition assay, as described in Example 13.
- lanes A, B and C contain different inhibitors.
- target nucleic acid region or “target nucleotide sequence” includes a probe-hybridizing region contained within the target molecule.
- target nucleic acid sequence includes a sequence with which a probe will form a stable hybrid under desired conditions.
- a "biological sample” refers to a sample of isolated cells, tissue or fluid, including but not limited to, for example, plasma, serum, spinal fluid, semen, lymph fluid, the external sections of the skin, respiratory, intestinal, and genitourinary tracts, tears, saliva, milk, blood cells, tumors, organs, and also samples of in viti o cell culture constituents (including but not limited to conditioned medium resulting from the growth of cells m cell culture medium, putatively virally infected cells, recombinant cells, and cell components)
- a "small molecule” is defined as including an organic or inorganic compound either synthesized in the laboratory or found in nature Typically, a small molecule is characterized in that it contains several carbon-carbon bonds, and has a molecular weight of less than 1500 grams/Mol
- barcode refers to one or more sizes, size distributions, compositions, or any combination thereof, of semiconductor nanocrystals.
- Each size, size distribution and/or composition of semiconductor nanocrystals has a characteristic emission spectrum, e.g., wavelength, intensity,
- Semiconductor nanocrystals demonstrate quantum confinement effects in their luminescent properties.
- a secondary emission of energy occurs of a frequency that corresponds to the bandgap of the semiconductor material used in the semiconductor nanocrystal.
- the bandgap energy is a function of the size and/or composition of the nanocrystal.
- a mixed population of semiconductor nanocrystals of various sizes and/or compositions can be excited simultaneously using a single wavelength of light and the detectable luminescence can be engineered to occur at a plurality of wavelengths.
- the luminescent emission is related to the size and/or the composition of the constituent semiconductor nanocrystals of the population.
- the surface of the core/shell semiconductor nanocrystal can be modified to produce semiconductor nanocrystals that can be coupled to a variety of biological molecules or substrates by techniques desc ⁇ bed in, for example, Bruchez et al (1998) Science 281 2013-2016, Chan et al (1998) Sc ⁇ ?/2ce 281 2016-2018, Bruchez “Luminescent Semiconductor Nanocrystals Intermittent Behavior and use as Fluorescent Biological Probes” (1998) Doctoral dissertation, University of California, Berkeley, Mikulec "Semiconductor Nanocrystal Colloids Manganese Doped Cadmium
- semiconductor nanocrystals can be used to detect or track a single target Additionally, a population of semiconductor nanocrystals may be used for either simultaneous detection of multiple targets or to detect particular compounds and/or items of interest in, e g , a library of compounds
- each semiconductor nanocrystal distribution is capable of emitting energy in narrow spectral linewidths, as narrow as 12 nm to 60 nm FWHM, and with a symmetric, nearly Gaussian line shape, thus providing an easy way to identify a particular semiconductor nanocrystal.
- the linewidths are dependent on the size heterogeneity, i.e., monodispersity, of the semiconductor nanocrystals in each preparation.
- Single semiconductor nanocrystal complexes have been observed to have FWHM as narrow as 12 nm to 15 nm.
- semiconductor nanocrystal distributions with larger linewidths in the range of 35 nm to 60 nm can be readily made and have the same physical characteristics as semiconductor nanocrystals with narrower linewidths.
- the nanocrystals For any particular composition selected for the semiconductor nanocrystals to be used in the inventive methods, it is possible to tune the emission to a desired wavelength by controlling the size of the particular composition of the semiconductor nanocrystal.
- 5-20 discrete emissions five to twenty different size populations or distributions distinguishable from one another
- more preferably 10-15 discrete emissions are obtained for any particular composition, although one of ordinary skill in the art will realize that fewer than five emissions and more than twenty emissions could be used depending on the monodispersity of the semiconductor nanocrystal particles.
- the nanocrystals are preferably substantially monodisperse within the size range given above.
- Suitable materials for the overcoating layer include semiconductor materials having a higher bandgap energy than the semiconductor nanocrystal core.
- suitable materials for the overcoating layer should have good conduction and valence band offset with respect to the core semiconductor nanocrystal.
- the conduction band is desirably higher and the valence band is desirably lower than those of the core semiconductor nanocrystal.
- the preparation of a coated semiconductor nanocrystal may be found in, e.g., Dabbousi et al. (1997) J. Phys. Chem. B 101:9463) and Kuno et al. (1997) J. Phys. Chem. 106:9869.
- the above method can be used to prepare separate populations of semiconductor nanocrystals, wherein each population exhibits a different characteristic photoluminescence spectrum.
- Each of a plurality of populations of semiconductor nanocrystals can be conjugated to distinct first members of binding pairs for use in a multiplexed assay or analytical method in which each of a plurality of corresponding second members of the binding pairs can be detected simultaneously.
- the hydrophobic region also provides a "pseudo- hydrophobic" environment for the nanocrystal and thereby shields it from aqueous surroundings.
- the hydrophilic moiety may be a polar or charged (positive or negative) group. The polarity or charge of the group provides the necessary hydrophilic interactions with water to provide stable solutions or suspensions of the semiconductor nanocrystal.
- a solid support can be any material that is an insoluble matrix and can have a rigid or semi-rigid surface.
- Exemplary solid supports include but are not limited to pellets, disks, capillaries, hollow fibers, needles, pins, solid fibers, cellulose beads, pore-glass beads, silica gels, polystyrene beads optionally cross-linked with divinylbenzene, grafted co-poly beads, polyacrylamide beads, latex beads, dimethylacrylamide beads optionally crosslinked with N-N'-bis- acryloylethylenediamine, and glass particles coated with a hydrophobic polymer.
- antibody fragments which retain the ability to recognize the analyte of interest, will also find use in the subject immunoassays.
- a number of antibody fragments are known in the art which comprise antigen-binding sites capable of exhibiting immunological binding properties of an intact antibody molecule.
- functional antibody fragments can be produced by cleaving a constant region, not responsible for antigen binding, from the antibody molecule, using e.g., pepsin, to produce F(ab'), fragments. These fragments will contain two antigen binding sites, but lack a portion of the constant region from each of the heavy chains.
- the analyte of interest can be detected using standard immunoassays such as competition, direct reaction, or sandwich type assays.
- assays include, but are not limited to, ELISA-like assays (termed QISA herein) and biotin/avidin type assays.
- the reactions include the semiconductor nanocrystals in order to detect the formation of a complex between the antigen and the antibody or antibodies reacted therewith.
- the aforementioned assays generally involve separation of unbound antibody in a liquid phase from a solid phase support to which labeled antigen-antibody complexes are bound.
- a solid support is first reacted with a component that will bind to the solid support, i.e., the "solid phase component," e.g., an antigen or an antibody, under suitable binding conditions such that the component is sufficiently immobilized to the support.
- immobilization to the support can be enhanced by first coupling the antigen or antibody to a protein with better solid phase-binding properties.
- Suitable coupling proteins include, but are not limited to, macromolecules such as serum albumins including bovine serum albumin (BSA), keyhole limpet hemocyanin, immunoglobulin molecules, thyroglobulin, ovalbumin, and other proteins well known to those skilled in the art.
- the presence of bound antibody ligands from a biological sample can be readily detected using a secondary binder comprising an antibody directed against the antibody ligands, conjugated to semiconductor nanocrystals.
- a secondary binder comprising an antibody directed against the antibody ligands, conjugated to semiconductor nanocrystals.
- Ig immunoglobulin
- competitive-type QISA techniques can be practiced using methods known to those skilled in the art.
- Probes for use in these assays are designed from either conserved or nonconserved regions of the target polynucleotide of interest, using techniques well known m the art Generally, probes are developed from nonconserved or unique regions when maximum specificity is desired, and from conserved regions when assaying for regions that are closely related to, for example, different members of a multigene family or in related species
- Polymerase chain reaction (PCR) is a technique for amplifying a desired target nucleic acid sequence contained in a nucleic acid molecule or mixture of molecules In PCR, a pair of p ⁇ mers is employed in excess to hybridize to the complementary strands of the target nucleic acid The p ⁇ mers are each extended by a polymerase usmg the target nucleic
- LCR Ligase Chain Reaction
- probe pairs are used which include two primary (first and second) and two secondary (third and fourth) probes, all of which are used in molar excess to target.
- the first probe hybridizes to a first segment of the target strand
- the second probe hybridizes to a second segment of the target strand, the first and second segments being contiguous so that the primary probes abut one another in 5' phosphate-3' hydroxyl relationship.
- a ligase can covalently fuse or ligate the two probes into a fused product.
- an oligonucleotide is constructed wherein an n-mer, preferably a randomized sequence of nucleotides thereby forming a "randomer pool" of oligonucleotides, is flanked by two polymerase chain reaction (PCR) primers.
- PCR polymerase chain reaction
- semiconductor nanocrystal-FISH probes can be use for in situ hyb ⁇ dization for DNA (see Example 5; see also Dewald et al. (1993) Bone Marrow Transplantation 12:149-154; Ward et al. (1993) Am J. Hum Genet 52:854-865, Jalal et al. (1998) Mayo Clin Proc 73:132-137, Zahed et al.
- FISH technologies are widely used in research and clinical molecular cytogenetics, pathology and immunology laboratories.
- Semiconductor nanocrystal- DNA probes can be use to detect amplification (e.g., HER2/neu, c myc genes amplification), addition (e.g., trisomy 21, 13, 18), deletion (e.g., 45X, Turner's Syndrome), translocation (e.g., BCR/ABL in CML) of DNA in the nuclei.
- amplification e.g., HER2/neu, c myc genes amplification
- addition e.g., trisomy 21, 13, 18
- deletion e.g., 45X, Turner's Syndrome
- translocation e.g., BCR/ABL in CML
- the conditions of the FISH assays exemplified below can be optimized depending on the nature of different probes (e.g., whether the nucleic acid sequence is highly repetitive or not) or mixtures of probes.
- the assays are carried out at room temperature to 100°C but are typically carried out in the range of 37°C to 80°C.
- Renaturation The stability of nucleic acid hybrids is dependent on environmental conditions; two of the most important of which are temperature and salt concentration. In general, DNA duplexes are more stable at lower temperatures and higher salt concentrations. When denatured DNA is cooled or subjected to higher salt concentrations, it will spontaneously renature. Under ideal renaturation conditions and given sufficient time, mixtures of single- stranded fragments of DNA will reassociate (hybridize) with their complementary sequences. This property of nucleic acids is the basis upon which the assays disclosed herein are founded.
- any portion of the solid support to which no antibody is bound is treated with an agent to reduce nonspecific binding thereto, e.g., 1% BSA + 1% antibody species 2 antiserum (e.g., an antibody that is distinct from the first capturing antibody species) in phosphate-buffered saline (PBS).
- an agent to reduce nonspecific binding thereto e.g., 1% BSA + 1% antibody species 2 antiserum (e.g., an antibody that is distinct from the first capturing antibody species) in phosphate-buffered saline (PBS).
- PBS phosphate-buffered saline
- a sample containing or suspected of containing the analyte of interest is added to the treated solid support and incubated for a time (30 seconds to 48 hours) sufficient to bind the analyte to the primary antibody.
- the support is again washed to remove nonspecific and unbound analyte molecules in the sample.
- Example 3 Fluid-Phase QISA This example describes a fluid-phase QISA in which a fluid-phase sample containing or suspected of containing an analyte of interest or a plurality of different analytes of interest, is adsorbed onto a solid-phase substrate and adsorbed analytes are detected using one or a plurality of semiconductor nanocrystal/analyte-specific antibody conjugates.
- This example describes a fluid-phase QISA in which a fluid-phase sample containing or suspected of containing an analyte of interest or a plurality of different analytes of interest, is incubated with and bound to a primary antibody, or a plurality of primary antibodies capable of specifically recognizing and binding to an analyte.
- the primary antibody is immobilized on a microsphere. Bound analyte or analytes are detected using one or a plurality of semiconductor nanocrystal/analyte-specific antibody conjugates.
- a primary polyclonal or monoclonal antibody (species 1) specific for the analyte to be detected in the sample is immobilized onto microspheres using well- established techniques.
- concentration of primary antibody should be appropriate for the assay (1 ng/ml to 10 mg/ml), as described in Example 1.
- the microspheres are washed to remove unbound primary antibody.
- This homogeneous assay format is advantageous in that it allows free association in solution of all the receptor-ligand pairs, each of which can be prepared to scintillate in a unique region of the spectrum.
- Semiconductor nanocrystals which emit in green, yellow, and red regions of the spectrum, and are well resolved spectrally are conjugated to three different ligands (receptor antagonists) to the IL-1, IL-5, and IL-12 receptors respectively.
- a solution is prepared which is 1 nM in each of these semiconductor nanocrystal-receptor antagonist conjugates. Aliquots are mixed with a concentration series of the inhibitor of interest, and brought to identical final volumes and concentrations of RA-semiconductor nanocrystals (0.75 nM each).
- the presence of semiconductor nanocrystals immobilized on the surface is detected by exciting at an allowed absorbance wavelength, and measuring at the semiconductor nanocrystal emission wavelength.
- the presence of a semiconductor nanocrystal emission on the surface is directly proportional to the amount of amplified target DNA present.
- Two PCR primer sequences are selected, such that they specifically amplify a portion of the target DNA sequence containing the region to be probed.
- the 5' end of each of the two primers is labeled with a semiconductor nanocrystal with peak emission at 525 nm.
- These two primers are used to amplify a defined portion of the target DNA in a standard PCR reaction. Since the semiconductor nanocrystal is conjugated to the primer, and the primer is extended to become the amplified target, the semiconductor nanocrystal is connected to the 5' end of the amplified target. After the thermal cycling the target can be denatured or made single-stranded by heating it for two minutes at 95°C.
- Two PCR primer sequences are selected for each of three targets. These primers are chosen such that each pair will specifically amplify a portion of the target DNA sequence containing the region complementary to the three DNA probes.
- the 5' end of each of the first pair of primers is labeled with a semiconductor nanocrystal with peak emission at 525 nm.
- the 5' end of each of the second pair of primers is labeled with a semiconductor nanocrystal with peak emission at 580 nm.
- the 5' end of each of the third pair of primers is labeled with a semiconductor nanocrystal with peak emission at 650 nm.
- the amplified target can be denatured or made single-stranded by heating for two minutes at 95°C.
- the DNA polymerase has no site for attachment, so extension will not occur. If the primer and amplified target sequences are complementary, sequence-specific extension will occur. If the extension reaction mixture includes a labeled dNTP(e.g., semiconductor nanocrystal-labeled dGTP), the presence or absence of extension can be detected. This allows a determination of the original target sequence.
- Two different DNA sequence specific primer sequences are chosen, such that the 3' end of the primers overlaps a SNP in the target DNA sequence by 2 nucleotides. These sequence can range from 15 to 25 nucleotides in length. The first sequence will be completely complementary to allele A, and will be called primer A. The second sequence will be completely complementary to allele B, and will be called primer B. Primer A and Primer B sequences are chemically synthesized and purified. The 5' end of primer A is conjugated to the surface of the well of a microtiter plate, using any one of a variety of standard chemical linkages.
- this primer B is conjugated to the surface of a second well of a microtiter plate, using any one of a variety of standard chemical linkages.
- a semiconductor nanocrystal-dGTP conjugate is prepared and purified.
- the semiconductor nanocrystal is chosen with 525 nm emission.
- Two PCR primer sequences are selected, such that they specifically amplify a portion of the target DNA sequence containing the SNP to be evaluated. These two primers are used to amplify a defined portion of the target DNA in a standard PCR reaction( AmpliTaq Polymerase, dNTPs, Magnesium Chloride, buffer and target DNA).
- a wash step under denaturing conditions is performed by adding 500 ⁇ l of 3X SSPE, and incubating for 5 minutes at 95°C. Rinse the well twice with water.
- the semiconductor nanocrystal with 525 emission is incorporated into the extension sequence, and is thus connected to the surface of the plate via the sequence-specific hybridization.
- the well is scanned in a fiuorimeter. UV light is shone upon the well, and the amount of phosphorescence at 525 nm is measured. The presence of 525 nm emission indicates that the immobilized probe captured semiconductor nanocrystal-labeled amplified target, and remained hybridized after the stringent wash and water rinse steps.
- Two oligonucleotide probes are hybridized to adjacent sequences of PCR amplified target DNA with the join situated at the position of a known mutation site.
- DNA ligase covalently joins the two oligonucleotide probes only if they are perfectly hybridized, which will occur if no mutation is present.
- Initial studies tagged one probe with biotin and the other with a reporter molecule such as digoxygenin. On transfer to streptavidin-coated microtiter plates washing will remove the reporter labeled probe unless ligation has occurred. Signal detection will therefore only occur if the mutation is not present.
- the wells of the microtiter plate are washed 3 times with water. In wells where the DNA ligation reaction occurred, the semiconductor nanocrystal with 525 nm emission will be immobilized to the bottom of the well. The well is scanned in a fiuorimeter. UV light is shone upon the well, and the amount of phosphorescence at 525 nm is measured.
- This assay provides information on the concentration of analyte(s) in any biological medium. It is especially useful for measuring multiple analytes in a diagnostic type test and may also be used for environmental, research or screening applications. The greater the concentration of analyte in the sample the greater the amount of fluorescence detected in the lower chamber. Thus, this system provides a desirable increasing curve in terms of analyte concentration.
- Figure 5 is a pictorial representation of a competitive microsphere filter assay as described herein.
Abstract
Description
Claims
Priority Applications (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2000616425A JP2002544488A (en) | 1999-05-07 | 2000-05-05 | Methods for detecting analytes using semiconductor nanocrystals |
EP00928836A EP1179185B1 (en) | 1999-05-07 | 2000-05-05 | A method of detecting an analyte using semiconductor nanocrystals |
AU47012/00A AU4701200A (en) | 1999-05-07 | 2000-05-05 | A method of detecting an analyte using semiconductor nanocrystals |
CA002373146A CA2373146A1 (en) | 1999-05-07 | 2000-05-05 | A method of detecting an analyte using semiconductor nanocrystals |
AT00928836T ATE439452T1 (en) | 1999-05-07 | 2000-05-05 | METHOD FOR DETECTING ANALYTES USING SEMICONDUCTOR NANOCRYSTALS |
DE60042738T DE60042738D1 (en) | 1999-05-07 | 2000-05-05 | PROCESS FOR DETECTING ANALYTES USING SEMICONDUCTOR ANOCRYSTALLES |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US13308499P | 1999-05-07 | 1999-05-07 | |
US60/133,084 | 1999-05-07 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2000068692A1 true WO2000068692A1 (en) | 2000-11-16 |
Family
ID=22456937
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2000/012227 WO2000068692A1 (en) | 1999-05-07 | 2000-05-05 | A method of detecting an analyte using semiconductor nanocrystals |
Country Status (8)
Country | Link |
---|---|
US (5) | US6274323B1 (en) |
EP (1) | EP1179185B1 (en) |
JP (1) | JP2002544488A (en) |
AT (1) | ATE439452T1 (en) |
AU (1) | AU4701200A (en) |
CA (1) | CA2373146A1 (en) |
DE (1) | DE60042738D1 (en) |
WO (1) | WO2000068692A1 (en) |
Cited By (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2001057522A2 (en) * | 2000-02-07 | 2001-08-09 | Quantum Dot Corporation | Immunochromatographic methods which employ semiconductor nanocrystals |
WO2001077391A1 (en) * | 2000-04-06 | 2001-10-18 | Quantum Dot Corporation | Spatial positioning of spectrally labeled beads |
WO2002043159A2 (en) * | 2000-10-19 | 2002-05-30 | Arch Development Corporation | Doped semiconductor nanocrystals |
EP1255866A1 (en) * | 2000-02-16 | 2002-11-13 | Quantum Dot Corporation | Microarray methods utilizing semiconductor nanocrystals |
WO2002099425A2 (en) * | 2001-06-06 | 2002-12-12 | Dynal Biotech Asa | Polymeric bead probe with nanocrystal, manufacture and use of the same |
WO2004008143A1 (en) * | 2002-07-12 | 2004-01-22 | Micronas Holding Gmbh | Method for determining the number of receptors on a carrier |
WO2004027095A1 (en) * | 2002-09-20 | 2004-04-01 | Intel Corporation | Controlled alignment of nanobarcodes encoding specific information for scanning probe microscopy (spm) reading |
EP1448800A2 (en) * | 2001-11-21 | 2004-08-25 | Applera Corporation | Digital assay |
WO2005012505A2 (en) * | 2003-07-23 | 2005-02-10 | Cellular Technology Ltd. | Nanoparticle and microparticle based detection of cellular products |
JP2005513497A (en) * | 2002-01-03 | 2005-05-12 | カール ツァイス イエナ ゲゼルシャフト ミット ベシュレンクテル ハフツング | Method and / or apparatus for identification of fluorescent, luminescent and / or light-absorbing substances on and / or in a sample carrier |
EP1546983A2 (en) * | 2002-09-20 | 2005-06-29 | Intel Corporation | Controlled aligment of nano-barcodes encoding specific information for scanning probe microscopy (spm) reading |
JP2005538353A (en) * | 2002-09-06 | 2005-12-15 | カイロン コーポレイション | Method for verifying fluid movement |
WO2008036217A1 (en) * | 2006-09-20 | 2008-03-27 | Nellcor Puritan Bennett Llc | System and method for practicing spectrophotometry using light emitting nanostructure devices |
EP2126072A1 (en) * | 2007-02-21 | 2009-12-02 | Life Technologies Corporation | Materials and methods for single molecule nucleic acid sequencing |
US8110403B2 (en) | 2008-02-12 | 2012-02-07 | Fujifilm Corporation | Immunoassay method |
US9063145B2 (en) | 2003-07-23 | 2015-06-23 | Cellular Technology Limited | Multivalent opsonophagocytic assay using bead array and imaging |
CN105353131A (en) * | 2015-10-23 | 2016-02-24 | 山东大学 | Cytokine multiple detection method based on dual coding and monomolecular counting |
WO2018213604A3 (en) * | 2017-05-18 | 2018-12-27 | Locus Agriculture Ip Company, Llc | Diagnostic assays for detecting, quantifying, and/or tracking microbes and other analytes |
US10308983B2 (en) | 2011-02-04 | 2019-06-04 | The Trustees of The University of Pennsylvnia | Method for detecting chromosome structure and gene expression simultaneously in single cells |
WO2020191480A1 (en) | 2019-03-28 | 2020-10-01 | Alentic Microscience Inc. | Bead-based analysis of a sample |
US11609233B2 (en) | 2019-03-28 | 2023-03-21 | Alentic Microscience Inc. | Indicator-based analysis of a sample |
US11692989B2 (en) | 2019-07-11 | 2023-07-04 | Locus Solutions Ipco, Llc | Use of soil and other environmental data to recommend customized agronomic programs |
US11719700B2 (en) | 2019-03-28 | 2023-08-08 | Alentic Microscience Inc. | Upconversion for microscopy |
US11733239B2 (en) | 2019-03-28 | 2023-08-22 | Alentic Microscience Inc. | Bead-based analysis of a sample |
Families Citing this family (338)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6607829B1 (en) | 1997-11-13 | 2003-08-19 | Massachusetts Institute Of Technology | Tellurium-containing nanocrystalline materials |
US6207392B1 (en) | 1997-11-25 | 2001-03-27 | The Regents Of The University Of California | Semiconductor nanocrystal probes for biological applications and process for making and using such probes |
US6582962B1 (en) * | 1998-02-27 | 2003-06-24 | Ventana Medical Systems, Inc. | Automated molecular pathology apparatus having independent slide heaters |
JP3662850B2 (en) * | 1998-06-24 | 2005-06-22 | イルミナ インコーポレイテッド | Decoding array sensors with microspheres |
US6617583B1 (en) * | 1998-09-18 | 2003-09-09 | Massachusetts Institute Of Technology | Inventory control |
EP1039291A1 (en) * | 1999-03-26 | 2000-09-27 | Sony International (Europe) GmbH | Optochemical sensor and method for its construction |
US7253435B2 (en) * | 1999-04-15 | 2007-08-07 | Millipore Corporation | Particles with light-polarizing codes |
US20030129654A1 (en) * | 1999-04-15 | 2003-07-10 | Ilya Ravkin | Coded particles for multiplexed analysis of biological samples |
US6908737B2 (en) * | 1999-04-15 | 2005-06-21 | Vitra Bioscience, Inc. | Systems and methods of conducting multiplexed experiments |
US20030166015A1 (en) * | 1999-04-15 | 2003-09-04 | Zarowitz Michael A. | Multiplexed analysis of cell-substrate interactions |
US20030207249A1 (en) * | 1999-04-15 | 2003-11-06 | Beske Oren E. | Connection of cells to substrates using association pairs |
US20030134330A1 (en) * | 1999-04-15 | 2003-07-17 | Ilya Ravkin | Chemical-library composition and method |
DE60042738D1 (en) * | 1999-05-07 | 2009-09-24 | Life Technologies Corp | PROCESS FOR DETECTING ANALYTES USING SEMICONDUCTOR ANOCRYSTALLES |
US6544732B1 (en) * | 1999-05-20 | 2003-04-08 | Illumina, Inc. | Encoding and decoding of array sensors utilizing nanocrystals |
US8481268B2 (en) | 1999-05-21 | 2013-07-09 | Illumina, Inc. | Use of microfluidic systems in the detection of target analytes using microsphere arrays |
US8080380B2 (en) | 1999-05-21 | 2011-12-20 | Illumina, Inc. | Use of microfluidic systems in the detection of target analytes using microsphere arrays |
US7192778B2 (en) * | 1999-10-06 | 2007-03-20 | Natan Michael J | Surface enhanced spectroscopy-active composite nanoparticles |
US8497131B2 (en) * | 1999-10-06 | 2013-07-30 | Becton, Dickinson And Company | Surface enhanced spectroscopy-active composite nanoparticles comprising Raman-active reporter molecules |
US8076063B2 (en) | 2000-02-07 | 2011-12-13 | Illumina, Inc. | Multiplexed methylation detection methods |
US7361488B2 (en) * | 2000-02-07 | 2008-04-22 | Illumina, Inc. | Nucleic acid detection methods using universal priming |
US7955794B2 (en) | 2000-09-21 | 2011-06-07 | Illumina, Inc. | Multiplex nucleic acid reactions |
WO2001057269A2 (en) | 2000-02-07 | 2001-08-09 | Illumina, Inc. | Nucleic acid detection methods using universal priming |
DE60127939T2 (en) | 2000-02-07 | 2008-01-24 | Illumina, Inc., San Diego | Nucleic acid detection method with universal priming |
US7582420B2 (en) | 2001-07-12 | 2009-09-01 | Illumina, Inc. | Multiplex nucleic acid reactions |
DE10006432A1 (en) * | 2000-02-14 | 2001-08-16 | Ganzimmun Inst Fuer Ganzheitli | Method for the detection of Helicobacter pylori in stool and saliva samples |
EP1967595A3 (en) | 2000-02-16 | 2008-12-03 | Illumina, Inc. | Parallel genotyping of multiple patient samples |
US6571028B1 (en) | 2000-03-21 | 2003-05-27 | Evident Technologies | Optical switch having a saturable absorber |
US20020090650A1 (en) * | 2000-04-06 | 2002-07-11 | Quantum Dot Corporation | Two-dimensional spectral imaging system |
AU2001257454A1 (en) * | 2000-04-28 | 2001-11-12 | Quantum Dot Corporation | Methods and compositions for polynucleotide analysis using generic capture sequences |
US20050192430A1 (en) * | 2000-05-24 | 2005-09-01 | Rosenthal Sandra J. | Linker arms for nanocrystals and compounds thereof |
US20050013775A1 (en) * | 2000-06-01 | 2005-01-20 | Kotov Nicholas A. | Bioconjugates of nanoparticles as radiopharmaceuticals |
US6689338B2 (en) * | 2000-06-01 | 2004-02-10 | The Board Of Regents For Oklahoma State University | Bioconjugates of nanoparticles as radiopharmaceuticals |
US6611640B2 (en) | 2000-10-03 | 2003-08-26 | Evident Technologies | Optical dispersion compensator |
US20050059031A1 (en) * | 2000-10-06 | 2005-03-17 | Quantum Dot Corporation | Method for enhancing transport of semiconductor nanocrystals across biological membranes |
ATE536550T1 (en) * | 2000-10-06 | 2011-12-15 | Life Technologies Corp | TRANSFECTABLE MICELLARS CONTAINING SEMICONDUCTOR NANOCRYSTALS |
JP2004537712A (en) | 2000-10-18 | 2004-12-16 | バーチャル・アレイズ・インコーポレーテッド | Multiple cell analysis system |
FI20002623A (en) * | 2000-11-30 | 2002-05-31 | Inno Trac Diagnostics Oy | Bioanalytical determination method |
US7171030B2 (en) * | 2000-11-30 | 2007-01-30 | University Of Medicine & Denistry Of New Jersey | Systems for analyzing microtissue arrays |
US6697548B2 (en) | 2000-12-18 | 2004-02-24 | Evident Technologies | Fabry-perot opitcal switch having a saturable absorber |
US6861263B2 (en) | 2001-01-26 | 2005-03-01 | Surromed, Inc. | Surface-enhanced spectroscopy-active sandwich nanoparticles |
US20020110180A1 (en) * | 2001-02-09 | 2002-08-15 | Barney Alfred A. | Temperature-sensing composition |
US6710911B2 (en) | 2001-03-02 | 2004-03-23 | Evident Technologies | Optical wavelength converter |
ATE448474T1 (en) * | 2001-03-09 | 2009-11-15 | Univ Reims Champagne Ardenne L | HIGHLY SENSITIVE NON-ISOTOPIC WATER SOLUBLE NANOCRYSTALS |
US6694158B2 (en) | 2001-04-11 | 2004-02-17 | Motorola, Inc. | System using a portable detection device for detection of an analyte through body tissue |
US7521019B2 (en) * | 2001-04-11 | 2009-04-21 | Lifescan, Inc. | Sensor device and methods for manufacture |
US6379622B1 (en) * | 2001-04-11 | 2002-04-30 | Motorola, Inc. | Sensor incorporating a quantum dot as a reference |
WO2002084271A2 (en) * | 2001-04-16 | 2002-10-24 | The Regents Of The University Of California | Methods and sensors for luminescent and optoelectronic detection and analysis of polynucleotides |
US7572642B2 (en) * | 2001-04-18 | 2009-08-11 | Ambrigen, Llc | Assay based on particles, which specifically bind with targets in spatially distributed characteristic patterns |
US20020164271A1 (en) * | 2001-05-02 | 2002-11-07 | Ho Winston Z. | Wavelength-coded bead for bioassay and signature recogniton |
DE10122836A1 (en) * | 2001-05-11 | 2002-11-28 | November Ag Molekulare Medizin | Security thread for forgery-proof marking of objects comprises a fiber to which a string of nucleic acid molecules is attached, such that they can be verified using a string of complementary molecules |
US7101910B2 (en) * | 2001-06-12 | 2006-09-05 | Wellstat Therapeutics Corporation | Compounds for the treatment of metabolic disorders |
US7095959B2 (en) | 2001-06-20 | 2006-08-22 | Evident Technologies | Optical time division multiplexing/demultiplexing system |
US20030013109A1 (en) * | 2001-06-21 | 2003-01-16 | Ballinger Clinton T. | Hairpin sensors using quenchable fluorescing agents |
EP1410031A2 (en) * | 2001-06-28 | 2004-04-21 | ADVANCED RESEARCH AND TECHNOLOGY INSTITUTE, Inc. | Methods of preparing multicolor quantum dot tagged beads and conjugates thereof |
US20030108949A1 (en) * | 2001-07-03 | 2003-06-12 | Gang Bao | Filtration-based microarray chip |
US7473767B2 (en) | 2001-07-03 | 2009-01-06 | The Institute For Systems Biology | Methods for detection and quantification of analytes in complex mixtures |
JP2003028797A (en) * | 2001-07-11 | 2003-01-29 | Hitachi Software Eng Co Ltd | Fluorescence reader |
US7110640B2 (en) | 2001-07-19 | 2006-09-19 | Evident Technologies | Reconfigurable optical add/drop filter |
EP1432825A4 (en) * | 2001-08-31 | 2005-02-09 | Minerva Biotechnologies Corp | Affinity tag modified particles |
US6542229B1 (en) | 2001-09-12 | 2003-04-01 | Peter J. Kalal | Sensors, methods of manufacture and sensing methods |
US20030219800A1 (en) * | 2001-10-18 | 2003-11-27 | Beske Oren E. | Multiplexed cell transfection using coded carriers |
US6838289B2 (en) * | 2001-11-14 | 2005-01-04 | Beckman Coulter, Inc. | Analyte detection system |
DE10156612A1 (en) * | 2001-11-20 | 2003-05-28 | Markus Klotz | To determine the presence of a substance, in a liquid or gas sample, a possible micro-particle size category is taken to be bonded with the sample substance by hybridizing for measurement by particle size/fluorescent light signals |
US20030143604A1 (en) * | 2001-11-30 | 2003-07-31 | Storhoff James J. | Real-time monitoring of PCR amplification using nanoparticle probes |
WO2003054234A1 (en) * | 2001-12-19 | 2003-07-03 | Roche Diagnostics Corporation | Pcr based high throughput polypeptide screening |
US20040171076A1 (en) * | 2001-12-20 | 2004-09-02 | Dejneka Matthew J. | Detectable micro to nano sized structures, methods of manufacture and use |
US7241629B2 (en) * | 2001-12-20 | 2007-07-10 | Corning Incorporated | Detectable labels, methods of manufacture and use |
US20040026684A1 (en) * | 2002-04-02 | 2004-02-12 | Nanosys, Inc. | Nanowire heterostructures for encoding information |
US8257967B2 (en) * | 2002-04-26 | 2012-09-04 | Board Of Regents, The University Of Texas System | Method and system for the detection of cardiac risk factors |
US8211657B2 (en) * | 2002-04-29 | 2012-07-03 | The Board Of Trustees Of The University Of Arkansas | Capillary-column-based bioseparator/bioreactor with an optical/electrochemical detector for detection of microbial pathogens |
US7998923B2 (en) * | 2002-05-07 | 2011-08-16 | The Regents Of The University Of California | Bioactivation of particles |
EP3312594B1 (en) | 2002-05-17 | 2019-07-24 | Life Technologies Corporation | Apparatus for differentiating multiple fluorescence signals by excitation wavelength |
EP1511990B1 (en) | 2002-05-17 | 2015-03-25 | Life Technologies Corporation | Instrument for detecting and measuring fluorescence including an excitation source |
US20040126773A1 (en) * | 2002-05-23 | 2004-07-01 | Beske Oren E. | Assays with coded sensor particles to sense assay conditions |
DE10224825A1 (en) * | 2002-06-05 | 2003-12-24 | Eppendorf Ag | Methods for the analysis of biomolecules |
US6730515B2 (en) * | 2002-06-11 | 2004-05-04 | Eastman Kodak Company | Micro-array calibration means |
US20030232340A1 (en) * | 2002-06-13 | 2003-12-18 | David Anderson | Nanoporous particle with a retained target |
GB2391230A (en) * | 2002-07-26 | 2004-02-04 | Smartbead Technologies Ltd | Multiparameter assays using coded supports |
US7810380B2 (en) | 2003-03-25 | 2010-10-12 | Tearlab Research, Inc. | Systems and methods for collecting tear film and measuring tear film osmolarity |
US8020433B2 (en) * | 2003-03-25 | 2011-09-20 | Tearlab Research, Inc. | Systems and methods for a sample fluid collection device |
WO2004016418A2 (en) * | 2002-08-14 | 2004-02-26 | Encap Technologies, Inc. | Microencapsulated and nanoencapsulated particles, moisture barrier resins, and processes for manufacturing same |
US7939170B2 (en) * | 2002-08-15 | 2011-05-10 | The Rockefeller University | Water soluble metal and semiconductor nanoparticle complexes |
WO2004035612A2 (en) * | 2002-09-04 | 2004-04-29 | Board Of Regents, University Of Texas System | Composition, method and use of bi-functional biomaterials |
US7176036B2 (en) * | 2002-09-20 | 2007-02-13 | Arrowhead Center, Inc. | Electroactive microspheres and methods |
CA2502246A1 (en) * | 2002-10-15 | 2004-04-29 | Abmetrix, Inc. | Sets of digital antibodies directed against short epitopes, and methods using same |
US9740817B1 (en) | 2002-10-18 | 2017-08-22 | Dennis Sunga Fernandez | Apparatus for biological sensing and alerting of pharmaco-genomic mutation |
US7192780B2 (en) * | 2002-10-23 | 2007-03-20 | Evident Technologies | Fluorescent lifetime biological detection and imaging using water-stable semiconductor nanocrystals |
US20040101822A1 (en) * | 2002-11-26 | 2004-05-27 | Ulrich Wiesner | Fluorescent silica-based nanoparticles |
JP2004184312A (en) * | 2002-12-05 | 2004-07-02 | Yokogawa Electric Corp | Biopolymer detection method and biochip |
WO2004065000A1 (en) | 2003-01-21 | 2004-08-05 | Illumina Inc. | Chemical reaction monitor |
US20040150217A1 (en) * | 2003-01-23 | 2004-08-05 | Heffelfinger David M. | Identifying indicia and focusing target |
JP4073323B2 (en) * | 2003-01-23 | 2008-04-09 | 日立ソフトウエアエンジニアリング株式会社 | Functional beads, reading method and reading apparatus thereof |
US20040175843A1 (en) * | 2003-03-04 | 2004-09-09 | Roitman Daniel B. | Near-field and far-field encoding and shaping of microbeads for bioassays |
US20040175842A1 (en) * | 2003-03-04 | 2004-09-09 | Roitman Daniel B. | Near-field and far-field encoding of microbeads for bioassays |
US7917298B1 (en) | 2003-04-17 | 2011-03-29 | Nanosys, Inc. | Nanocrystal taggants |
US20050026181A1 (en) * | 2003-04-29 | 2005-02-03 | Genvault Corporation | Bio bar-code |
US20040219533A1 (en) * | 2003-04-29 | 2004-11-04 | Jim Davis | Biological bar code |
WO2005016824A2 (en) * | 2003-05-05 | 2005-02-24 | The Research Foundation Of State University Of Newyork | Synthesis of nanoparticles by an emulsion-gas contacting process |
EP1658506A2 (en) * | 2003-08-18 | 2006-05-24 | Tethys Bioscience, Inc. | Methods for reducing complexity of a sample using small epitope antibodies |
US8346482B2 (en) * | 2003-08-22 | 2013-01-01 | Fernandez Dennis S | Integrated biosensor and simulation system for diagnosis and therapy |
US7488451B2 (en) * | 2003-09-15 | 2009-02-10 | Millipore Corporation | Systems for particle manipulation |
WO2005028621A2 (en) * | 2003-09-15 | 2005-03-31 | Vitra Bioscience, Inc. | Assays with primary cells |
US20050069900A1 (en) * | 2003-09-25 | 2005-03-31 | Cytyc Corporation | Analyte sample detection |
JP2007517500A (en) | 2003-10-15 | 2007-07-05 | ボード・オブ・リージエンツ,ザ・ユニバーシテイ・オブ・テキサス・システム | Multifunctional biological materials as scaffolds for electronic, optical, magnetic, semiconductor, and biotechnology applications |
EP1678495A4 (en) * | 2003-10-20 | 2007-06-27 | Univ California | Nanoscale transduction systems for detecting molecular interactions |
AU2003285133A1 (en) * | 2003-11-05 | 2005-06-24 | The Government Of The United States Of America As Represented By The Secretary Of Health And Human Services | Biofunctionalized quantum dots for biological imaging |
AU2004289210B2 (en) * | 2003-11-05 | 2010-07-15 | The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Carbohydrate antigen-nanoparticle conjugates and uses thereof as antimetastatic agents in treating cancer |
AU2004300168A1 (en) | 2003-12-11 | 2005-06-30 | Board Of Regents, The University Of Texas System | Method and system for the analysis of saliva using a sensor array |
US20050147963A1 (en) * | 2003-12-29 | 2005-07-07 | Intel Corporation | Composite organic-inorganic nanoparticles and methods for use thereof |
US20050191665A1 (en) * | 2003-12-29 | 2005-09-01 | Xing Su | Composite organic-inorganic nanoclusters |
US8101431B2 (en) | 2004-02-27 | 2012-01-24 | Board Of Regents, The University Of Texas System | Integration of fluids and reagents into self-contained cartridges containing sensor elements and reagent delivery systems |
US8105849B2 (en) | 2004-02-27 | 2012-01-31 | Board Of Regents, The University Of Texas System | Integration of fluids and reagents into self-contained cartridges containing sensor elements |
WO2005085850A1 (en) * | 2004-02-27 | 2005-09-15 | Tianxin Wang | Methods for multiplexed analyte detection |
US7745001B2 (en) * | 2004-03-23 | 2010-06-29 | University Of New Orleans Research And Technology Foundation, Inc. | Synthesis of nanoassemblies containing luminescent quantum dots and magnetic nanoparticles |
WO2006071247A2 (en) * | 2004-03-30 | 2006-07-06 | California Institute Of Technology | Diagnostic assays including multiplexed lateral flow immunoassays with quantum dots |
US20080032420A1 (en) * | 2004-03-30 | 2008-02-07 | Lambert James L | Surface Enhanced Raman Scattering and Multiplexed Diagnostic Assays |
US20050221504A1 (en) * | 2004-04-01 | 2005-10-06 | Petruno Patrick T | Optoelectronic rapid diagnostic test system |
US20070185679A1 (en) * | 2004-04-01 | 2007-08-09 | Petruno Patrick T | Indicating status of a diagnostic test system |
US8128871B2 (en) * | 2005-04-22 | 2012-03-06 | Alverix, Inc. | Lateral flow assay systems and methods |
US20070143035A1 (en) * | 2005-12-19 | 2007-06-21 | Petruno Patrick T | Diagnostic test reader with disabling unit |
US7521259B2 (en) * | 2004-04-01 | 2009-04-21 | Alverix, Inc. | Assay test strips with multiple labels and reading same |
US7280204B2 (en) * | 2004-04-08 | 2007-10-09 | Purdue Research Foundation | Multi-spectral detector and analysis system |
EP1584914A1 (en) * | 2004-04-08 | 2005-10-12 | Sony Deutschland GmbH | A method of detecting a hybrid, formed of at least two species, on a substrate using ellipsometry |
WO2006093516A2 (en) * | 2004-06-22 | 2006-09-08 | The Regents Of The University Of California | Peptide-coated nanoparticles with graded shell compositions |
US20060154380A1 (en) * | 2004-06-23 | 2006-07-13 | Shunji Egusa | Synthesis of ordered arrays from gold clusters |
US20060194198A1 (en) * | 2004-06-29 | 2006-08-31 | Carlo Licata | Use of fibrous protein fibers for chemical sensing and radiation detection |
KR100724314B1 (en) | 2004-07-22 | 2007-06-04 | 주식회사 엘지생명과학 | Ball shaped photonic crystal attaching with bioreceptor, preparation method thereof and using method thereof |
US7229690B2 (en) * | 2004-07-26 | 2007-06-12 | Massachusetts Institute Of Technology | Microspheres including nanoparticles |
US20060024744A1 (en) * | 2004-07-28 | 2006-02-02 | Mills Rhonda A | Methods for substantially simultaneous evaluation of a sample containing a cellular target and a soluble analyte |
US20060129327A1 (en) * | 2004-07-29 | 2006-06-15 | Kim Myung L | Ultrasensitive sensor and rapid detection of analytes |
US7405002B2 (en) | 2004-08-04 | 2008-07-29 | Agency For Science, Technology And Research | Coated water-soluble nanoparticles comprising semiconductor core and silica coating |
CA2520670A1 (en) * | 2004-09-23 | 2006-03-23 | National Research Council Of Canada | Nanocrystal coated surfaces |
US7534489B2 (en) * | 2004-09-24 | 2009-05-19 | Agency For Science, Technology And Research | Coated composites of magnetic material and quantum dots |
US7682782B2 (en) * | 2004-10-29 | 2010-03-23 | Affymetrix, Inc. | System, method, and product for multiple wavelength detection using single source excitation |
US8202479B1 (en) * | 2004-11-09 | 2012-06-19 | Applied Biosystems, Llc | Light collection system |
US20060240590A1 (en) * | 2004-11-09 | 2006-10-26 | The Research Foundation Of State University Of New York | Controlled synthesis of nanowires, nanodiscs, and nanostructured materials using liquid crystalline templates |
US20060131361A1 (en) * | 2004-12-16 | 2006-06-22 | Eastman Paul S | Quantum dot-encoded bead set for calibration and quantification of multiplexed assays, and methods for their use |
US20060148103A1 (en) * | 2004-12-30 | 2006-07-06 | Yin-Peng Chen | Highly sensitive biological assays |
US8569042B2 (en) * | 2005-02-23 | 2013-10-29 | Alcatel Lucent | DNA structures on ferroelectrics and semiconductors |
WO2006093892A2 (en) * | 2005-02-28 | 2006-09-08 | Gen-Probe Incorporated | Compositions and methods of detecting an analyte by using a nucleic acid hybridization switch probe |
US20100116664A1 (en) | 2005-03-08 | 2010-05-13 | Ignatius Michael J | Monitoring and manipulating cellular transmembrane potentials using nanostructures |
EP1861697A4 (en) * | 2005-03-10 | 2010-11-03 | Commercialisation Des Produits | Quantum dot template for fast and simultaneous detection of different infectious agents |
WO2006105102A2 (en) * | 2005-03-28 | 2006-10-05 | The Research Foundation Of State University Of New York | Synthesis of nanostructured materials using liquid crystalline templates |
US20080166706A1 (en) * | 2005-03-30 | 2008-07-10 | Jin Zhang | Novel gold nanoparticle aggregates and their applications |
US20070026391A1 (en) * | 2005-04-11 | 2007-02-01 | Ghc Technologies, Inc. | Methods and compositions for identifying chemical or biological agents using multiplexed labeling and colocalization detection |
US10041941B2 (en) * | 2005-04-22 | 2018-08-07 | Alverix, Inc. | Assay test strips with multiple labels and reading same |
CA2609702C (en) * | 2005-04-28 | 2013-05-28 | Ventana Medical Systems, Inc. | Antibody conjugates via heterobifunctional peg linkers |
AU2006239154A1 (en) * | 2005-04-28 | 2006-11-02 | Ventana Medical Systems, Inc | Nanoparticle conjugates |
US8084001B2 (en) * | 2005-05-02 | 2011-12-27 | Cornell Research Foundation, Inc. | Photoluminescent silica-based sensors and methods of use |
AU2006309284B2 (en) | 2005-05-31 | 2012-08-02 | Board Of Regents, The University Of Texas System | Methods and compositions related to determination and use of white blood cell counts |
CA2611743C (en) | 2005-06-15 | 2019-12-31 | Callida Genomics, Inc. | Nucleic acid analysis by forming and tracking aliquoted fragments of a target polynucleotide |
US8232092B2 (en) * | 2005-08-09 | 2012-07-31 | Maxwell Sensors, Inc. | Apparatus and method for digital magnetic beads analysis |
US7871770B2 (en) | 2005-08-09 | 2011-01-18 | Maxwell Sensors, Inc. | Light transmitted assay beads |
US7858307B2 (en) * | 2005-08-09 | 2010-12-28 | Maxwell Sensors, Inc. | Light transmitted assay beads |
US20070043510A1 (en) * | 2005-08-19 | 2007-02-22 | Beckman Coulter, Inc. | Assay system |
EP1951900B1 (en) | 2005-10-07 | 2016-06-15 | Callida Genomics, Inc. | Self-assembled single molecule arrays and uses thereof |
AU2007249635B2 (en) * | 2005-10-07 | 2012-05-31 | Complete Genomics, Inc. | High throughput genome sequencing on DNA arrays |
EP1954838B1 (en) * | 2005-11-14 | 2014-02-26 | Life Technologies Corporation | Coded molecules for detecting target analytes |
US20090298197A1 (en) * | 2005-11-15 | 2009-12-03 | Oxonica Materials Inc. | Sers-based methods for detection of bioagents |
US7772009B2 (en) * | 2005-11-22 | 2010-08-10 | SCR Research, LLC | Room temperature phosphorescence apparatus and methods |
US8632730B2 (en) * | 2005-11-22 | 2014-01-21 | Alverix, Inc. | Assaying test strips having different capture reagents |
WO2007062177A2 (en) | 2005-11-23 | 2007-05-31 | Ventana Medical Systems, Inc. | Molecular conjugate |
US20070122914A1 (en) * | 2005-11-30 | 2007-05-31 | Curry Bo U | Obtaining measurements of light transmitted through an assay test strip |
JP4654414B2 (en) * | 2005-12-01 | 2011-03-23 | 独立行政法人産業技術総合研究所 | Immunochemical detection method and reagent kit for the detection |
US8409863B2 (en) | 2005-12-14 | 2013-04-02 | Becton, Dickinson And Company | Nanoparticulate chemical sensors using SERS |
AU2006330830B2 (en) | 2005-12-23 | 2013-01-10 | Institute For Systems Biology | Nanoreporters and methods of manufacturing and use thereof |
US7723100B2 (en) | 2006-01-13 | 2010-05-25 | Becton, Dickinson And Company | Polymer coated SERS nanotag |
US7226752B1 (en) | 2006-01-19 | 2007-06-05 | Avago Technologies General Ip (Singapore) Pte. Ltd. | Methods for detecting an analyte in a sample |
EP1977242B1 (en) * | 2006-01-27 | 2016-08-03 | Becton Dickinson and Company | Lateral flow immunoassay with encapsulated detection modality |
WO2008085182A2 (en) * | 2006-02-02 | 2008-07-17 | University Of Wyoming | Supra nanoparticle assemblies and methods of making and using the assemblies |
US9274108B2 (en) | 2006-02-06 | 2016-03-01 | Massachusetts Institute Of Technology | Self-assembly of macromolecules on multilayered polymer surfaces |
WO2007095279A2 (en) * | 2006-02-14 | 2007-08-23 | University Of Florida Research Foundation, Inc. | Dual nanoparticle assay for detection and separation of biological species |
CA2571904A1 (en) * | 2006-02-15 | 2007-08-15 | Fio Corporation | System and method of detecting pathogens |
US20070188736A1 (en) * | 2006-02-16 | 2007-08-16 | Fouquet Julie E | Obtaining measurement and baseline signals for evaluating assay test strips |
US8460879B2 (en) | 2006-02-21 | 2013-06-11 | The Trustees Of Tufts College | Methods and arrays for target analyte detection and determination of target analyte concentration in solution |
SG170028A1 (en) * | 2006-02-24 | 2011-04-29 | Callida Genomics Inc | High throughput genome sequencing on dna arrays |
EP1996942A1 (en) * | 2006-03-10 | 2008-12-03 | Tethys Bioscience, Inc. | Multiplex protein fractionation |
US7807265B2 (en) * | 2006-05-12 | 2010-10-05 | University Of Central Florida Research Foundation, Inc. | Partially passivated quantum dots, process for making, and sensors therefrom |
EP2027442A2 (en) * | 2006-05-16 | 2009-02-25 | Applied Biosystems, Inc. | Systems, methods, and apparatus for single molecule sequencing |
JP5200931B2 (en) * | 2006-05-26 | 2013-06-05 | コニカミノルタエムジー株式会社 | III-V type semiconductor / SiO2 type nanoparticle and biological material labeling agent |
US20100130367A1 (en) * | 2006-07-11 | 2010-05-27 | Drexel University | Methods of Quantitatively Assessing Inflammation with Biosensing Nanoparticles |
JP5277165B2 (en) * | 2006-07-24 | 2013-08-28 | ベクトン・ディキンソン・アンド・カンパニー | Analytical particle agglomeration and imaging apparatus and method |
US7764361B2 (en) * | 2006-07-27 | 2010-07-27 | Northwestern University | Systems and methods to analyze multiplexed bead-based assays using backscattered light |
US8110407B2 (en) * | 2006-09-14 | 2012-02-07 | Konica Minolta Medical & Graphic, Inc. | Fluorescent semiconductor microparticle assembly, fluorescent labeling agent assembly for biological substance, and bioimaging method and biological substance analysis method using the assemblies |
WO2008070352A2 (en) | 2006-10-27 | 2008-06-12 | Complete Genomics, Inc. | Efficient arrays of amplified polynucleotides |
ES2761949T3 (en) * | 2006-11-01 | 2020-05-21 | Ventana Med Syst Inc | Haptens, hapten conjugates, compositions thereof and method for their preparation and use |
US20090111705A1 (en) | 2006-11-09 | 2009-04-30 | Complete Genomics, Inc. | Selection of dna adaptor orientation by hybrid capture |
CA2580589C (en) | 2006-12-19 | 2016-08-09 | Fio Corporation | Microfluidic detection system |
US8244021B2 (en) * | 2006-12-20 | 2012-08-14 | Ventana Medical Systems, Inc. | Quantitative, multispectral image analysis of tissue specimens stained with quantum dots |
US20080216894A1 (en) * | 2007-01-08 | 2008-09-11 | Plextronics, Inc. | Quantum dot photovoltaic device |
CA2682826C (en) | 2007-04-02 | 2013-08-13 | Fio Corporation | System and method of deconvolving multiplexed fluorescence spectral signals generated by quantum dot optical coding technology |
JP4357544B2 (en) * | 2007-05-15 | 2009-11-04 | シャープ株式会社 | Group 13 nitride phosphor and method for producing the same |
JP2010530912A (en) | 2007-06-22 | 2010-09-16 | フィオ コーポレイション | Manufacturing system and method for polymer microbeads doped with quantum dots |
JP5507454B2 (en) | 2007-07-09 | 2014-05-28 | フィオ コーポレイション | System and method for improved fluorescence detection of target molecules in a test sample |
US20090045360A1 (en) * | 2007-08-13 | 2009-02-19 | Xerox Corporation | Quantum dot-based luminescent marking material |
JP5658563B2 (en) * | 2007-08-17 | 2015-01-28 | マサチューセッツ インスティテュート オブ テクノロジー | Luminescent material |
JP5628037B2 (en) | 2007-10-12 | 2014-11-19 | フィオ コーポレイション | Flow focusing method and system for forming concentrated microbeads, and microbeads formed in the system |
WO2009055617A1 (en) * | 2007-10-23 | 2009-04-30 | Stratos Genomics Inc. | High throughput nucleic acid sequencing by spacing |
WO2009054244A1 (en) * | 2007-10-26 | 2009-04-30 | Konica Minolta Medical & Graphic, Inc. | Aggregate of semiconductor nanoparticle phosphor and method for observing single molecule |
WO2009067595A1 (en) * | 2007-11-20 | 2009-05-28 | 3M Innovative Properties Company | Method of analyzing a sample for a bacterium using diacetylene-containing polymer sensor |
JP2009128136A (en) * | 2007-11-22 | 2009-06-11 | Fujifilm Corp | Fluorescence detection method |
US20100304502A1 (en) * | 2007-12-05 | 2010-12-02 | Konica Minolta Medical & Graphic, Inc. | Detection method and detection kit |
KR101588736B1 (en) | 2008-01-10 | 2016-01-26 | 리서치 디벨롭먼트 파운데이션 | Vaccines and diagnostics for Ehrlichia chaffeensis |
WO2009145813A1 (en) * | 2008-03-04 | 2009-12-03 | Qd Vision, Inc. | Particles including nanoparticles, uses thereof, and methods |
US8834797B2 (en) * | 2008-04-04 | 2014-09-16 | Life Technologies Corporation | Scanning system and method for imaging and sequencing |
WO2009128938A1 (en) * | 2008-04-17 | 2009-10-22 | Maxwell Sensors, Inc. | Hydrodynamic focusing for analyzing rectangular microbeads |
CN102119331A (en) | 2008-06-05 | 2011-07-06 | 生命科技公司 | Activation and monitoring of cellular transmembrane potentials |
BRPI0915514A2 (en) | 2008-06-25 | 2016-01-26 | Fio Corp | biohazard warning infrastructure system and method, biohazard warning device and a method for alerting a user |
EP2303771B1 (en) * | 2008-06-30 | 2018-05-30 | Life Technologies Corporation | Methods for isolating and purifying nanoparticles from a complex medium |
WO2010003059A2 (en) * | 2008-07-02 | 2010-01-07 | Life Technologies Corporation | Stable indium-containing semiconductor nanocrystals |
ES2614810T3 (en) | 2008-08-14 | 2017-06-02 | Nanostring Technologies, Inc | Stable nano-indicators |
RU2515209C2 (en) | 2008-08-29 | 2014-05-10 | Эф-Ай-Оу Корпорейшн | Disposable portable diagnostic instrument and appropriate system and method to investigate biological and natural samples |
WO2010043927A1 (en) * | 2008-10-13 | 2010-04-22 | Xeptagen Spa | Method for the preparation of immunoconjugates and use thereof |
CN102197305B (en) * | 2008-10-23 | 2014-02-19 | 皇家飞利浦电子股份有限公司 | Colour management for biological samples |
CN104374932A (en) | 2009-01-13 | 2015-02-25 | Fio公司 | A handheld diagnostic test device used with an electronic device and a test cartridge in a rapid diagnostic test |
US10290387B2 (en) * | 2009-01-20 | 2019-05-14 | University Of Utah Research Foundation | Modification of colloidal nanocrystals |
WO2010085463A1 (en) * | 2009-01-20 | 2010-07-29 | University Of Utah Research Foundation | Post-synthesis modification of colloidal nanocrystals |
WO2010085658A1 (en) * | 2009-01-23 | 2010-07-29 | Drexel University | Apparatus and methods for detecting inflammation using quantum dots |
WO2011031876A1 (en) | 2009-09-09 | 2011-03-17 | Qd Vision, Inc. | Formulations including nanoparticles |
EP2475717A4 (en) | 2009-09-09 | 2015-01-07 | Qd Vision Inc | Particles including nanoparticles, uses thereof, and methods |
DE102009041967A1 (en) * | 2009-09-17 | 2011-03-24 | Lre Medical Gmbh | Apparatus for analyzing body fluids, is provided with light source, and fluorescence standard with sensor unit for detecting portion of fluorescence standard emitted light |
AU2010306862B2 (en) | 2009-10-13 | 2015-08-27 | Nanostring Technologies, Inc. | Protein detection via nanoreporters |
WO2011072228A1 (en) * | 2009-12-11 | 2011-06-16 | Massachusetts Institute Of Technology | Spectral imaging of photoluminescent materials |
CN102782156A (en) | 2009-12-31 | 2012-11-14 | 文塔纳医疗系统公司 | Methods for producing uniquely specific nucleic acid probes |
AU2011215753B2 (en) | 2010-02-11 | 2015-09-03 | Nanostring Technologies, Inc. | Compositions and methods for the detection of small RNAs |
EP2539355B1 (en) | 2010-02-26 | 2016-10-05 | Ventana Medical Systems, Inc. | In-situ hybridization with polytag probes |
CA2786853A1 (en) | 2010-02-26 | 2011-09-01 | Ventana Medical Systems, Inc. | Cytogenic analysis of metaphase chromosomes |
CA2812500A1 (en) | 2010-10-22 | 2012-04-26 | Simone Budow | A conjugate between a thiophilic solid phase and an oligonucleotide comprising a thiooxonucleotide |
EP2686438B1 (en) | 2011-03-14 | 2018-04-18 | Ventana Medical Systems, Inc. | A method of analyzing chromosomal translocations and a system therefor |
US9758834B2 (en) | 2011-03-28 | 2017-09-12 | Nanostring Technologies, Inc. | Compositions and methods for diagnosing cancer |
AU2012251027B2 (en) | 2011-05-04 | 2015-03-26 | Htg Molecular Diagnostics, Inc. | Quantitative nuclease protection Assay (qNPA) and sequencing (qNPS) improvements |
CN103906535B (en) | 2011-08-15 | 2017-07-14 | 芝加哥大学 | The composition related to the antibody of staphylococcal protein A and method |
WO2013057586A1 (en) | 2011-10-19 | 2013-04-25 | Oslo Universitetssykehus Hf | Compositions and methods for producing soluble t - cell receptors |
WO2013108126A2 (en) | 2012-01-16 | 2013-07-25 | University Of Oslo | Methyltransferases and uses thereof |
NZ702282A (en) | 2012-04-26 | 2016-07-29 | Univ Chicago | Compositions and methods related to antibodies that neutralize coagulase activity during staphylococcus aureus disease |
WO2013167387A1 (en) | 2012-05-10 | 2013-11-14 | Ventana Medical Systems, Inc. | Uniquely specific probes for pten, pik3ca, met, top2a, and mdm2 |
PL2872646T3 (en) | 2012-07-12 | 2018-03-30 | Institut National De La Santé Et De La Recherche Médicale (Inserm) | Methods for predicting the survival time and treatment responsiveness of a patient suffering from a solid cancer with a signature of at least 7 genes |
WO2014048942A1 (en) | 2012-09-25 | 2014-04-03 | Ventana Medical Systems, Inc. | Probes for pten, pik3ca, met, and top2a, and method for using the probes |
US9759722B2 (en) * | 2012-12-17 | 2017-09-12 | Leukodx Ltd. | Systems and methods for determining a chemical state |
US10610861B2 (en) | 2012-12-17 | 2020-04-07 | Accellix Ltd. | Systems, compositions and methods for detecting a biological condition |
WO2014097287A1 (en) | 2012-12-17 | 2014-06-26 | Leukodx, Ltd. | Systems and methods for detecting a biological condition |
US11366061B2 (en) | 2013-01-24 | 2022-06-21 | Grace Bio-Labs, Inc. | Protein microarray assay imager |
WO2014134508A1 (en) * | 2013-03-01 | 2014-09-04 | Rarecyte, Inc. | Monochromatic dot ensembles |
WO2014144666A2 (en) | 2013-03-15 | 2014-09-18 | The University Of Chicago | Methods and compositions related to t-cell activity |
WO2015036405A1 (en) | 2013-09-10 | 2015-03-19 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for diagnosing and treating basal cell carcinoma |
US10378044B1 (en) * | 2013-10-01 | 2019-08-13 | FemtoDx | Methods for increasing the molecular specificity of a nanosensor |
EP3066218B1 (en) | 2013-11-05 | 2018-12-26 | HTG Molecular Diagnostics, Inc. | Methods for detecting nucleic acids |
AU2015220784B2 (en) | 2014-02-24 | 2021-02-04 | Ventana Medical Systems, Inc. | Automated RNA detection using labeled 2'-O-methyl RNA oligonucleotide probes and signal amplification systems |
EP3121291A4 (en) * | 2014-03-20 | 2017-08-30 | Konica Minolta, Inc. | Probe reagent and fish using probe reagent |
EP3198257B1 (en) | 2014-09-23 | 2020-08-12 | Tearlab Research, Inc. | System for integration of microfluidic tear collection and lateral flow analysis of analytes of interest |
EP3009147A1 (en) | 2014-10-16 | 2016-04-20 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Method for treating resistant glioblastoma |
WO2016113233A1 (en) | 2015-01-12 | 2016-07-21 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for the diagnosis of pancreatic cancer |
US9909972B2 (en) * | 2016-02-08 | 2018-03-06 | MANTA Instruments, Inc. | Multi-camera apparatus for observation of microscopic movements and counting of particles in colloids and its calibration |
SG10202107055SA (en) | 2015-07-17 | 2021-08-30 | Nanostring Technologies Inc | Simultaneous quantification of a plurality of proteins in a user-defined region of a cross-sectioned tissue |
US10640816B2 (en) | 2015-07-17 | 2020-05-05 | Nanostring Technologies, Inc. | Simultaneous quantification of gene expression in a user-defined region of a cross-sectioned tissue |
WO2017029391A1 (en) | 2015-08-20 | 2017-02-23 | INSERM (Institut National de la Santé et de la Recherche Médicale) | New method for treating cancer |
WO2017055327A1 (en) | 2015-09-29 | 2017-04-06 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for quantifying the population of endothelial cells in a tissue sample |
WO2017055324A1 (en) | 2015-09-29 | 2017-04-06 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for quantifying the population of cells of monocytic origin in a tissue sample |
WO2017055322A1 (en) | 2015-09-29 | 2017-04-06 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for quantifying the population of neutrophils in a tissue sample |
WO2017055326A1 (en) | 2015-09-29 | 2017-04-06 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for quantifying the population of myeloid dendritic cells in a tissue sample |
WO2017055325A1 (en) | 2015-09-29 | 2017-04-06 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for quantifying the population of nk cells in a tissue sample |
WO2017055321A1 (en) | 2015-09-29 | 2017-04-06 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for quantifying the population of fibroblasts in a tissue sample |
WO2017055319A1 (en) | 2015-09-29 | 2017-04-06 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for quantifying the population of b cells in a tissue sample |
WO2017055320A1 (en) | 2015-09-29 | 2017-04-06 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for quantifying the population of cytotoxic lymphocytes in a tissue sample |
WO2017060397A1 (en) | 2015-10-09 | 2017-04-13 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for predicting the survival time of subjects suffering from melanoma metastases |
WO2017067944A1 (en) | 2015-10-19 | 2017-04-27 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for predicting the survival time of subjects suffering from triple negative breast cancer |
CN108449995B (en) | 2015-11-06 | 2022-02-01 | 文塔纳医疗系统公司 | Representative diagnosis |
US10793909B2 (en) | 2015-11-10 | 2020-10-06 | Inserm (Institut National De La Sante Et De La Recherche Medicale) | Methods for predicting the survival time of patients with decompensated alcoholic cirrhosis |
SG11201804648RA (en) | 2015-12-04 | 2018-06-28 | Univ Texas | Slc45a2 peptides for immunotherapy |
WO2017122039A1 (en) | 2016-01-13 | 2017-07-20 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for predicting pancreatic cancer treatment response |
WO2017182834A1 (en) | 2016-04-19 | 2017-10-26 | INSERM (Institut National de la Santé et de la Recherche Médicale) | New method for treating resistant glioblastoma |
WO2017202962A1 (en) | 2016-05-24 | 2017-11-30 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and pharmaceutical compositions for the treatment of non small cell lung cancer (nsclc) that coexists with chronic obstructive pulmonary disease (copd) |
US11060147B2 (en) | 2016-06-14 | 2021-07-13 | Inserm (Institut National De La Sante Et De La Recherche Medicale) | Methods for predicting acute severe colitis treatment response |
WO2018011107A1 (en) | 2016-07-11 | 2018-01-18 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Use of er-alpha 46 in methods and kits for assessing the status of breast cancer |
WO2018011166A2 (en) | 2016-07-12 | 2018-01-18 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for quantifying the population of myeloid dendritic cells in a tissue sample |
NL2017437B1 (en) * | 2016-09-08 | 2018-03-27 | Univ Amsterdam | Multi-chromatic capped semiconductor nanocrystals |
WO2018046738A1 (en) | 2016-09-12 | 2018-03-15 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for predicting the survival time of patients suffering from cancer |
WO2018046736A1 (en) | 2016-09-12 | 2018-03-15 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for predicting the survival time of patients suffering from cancer |
WO2018054960A1 (en) | 2016-09-21 | 2018-03-29 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for predicting and treating resistance to chemotherapy in npm-alk(+) alcl |
US20200016177A1 (en) | 2016-09-22 | 2020-01-16 | Inserm (Institut National De La Sante Et De La Recherche Medicale) | Methods and pharmaceutical compositions for reprograming immune environment in a subject in need thereof |
US10241111B2 (en) | 2016-10-21 | 2019-03-26 | AhuraTech LLC | Electroluminescent binding assays |
CA3043489A1 (en) | 2016-11-21 | 2018-05-24 | Nanostring Technologies, Inc. | Chemical compositions and methods of using same |
DE102016124692B4 (en) | 2016-12-16 | 2019-05-16 | Gna Biosolutions Gmbh | Method and system for amplifying a nucleic acid |
WO2018122245A1 (en) | 2016-12-28 | 2018-07-05 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods of predicting the survival time of patients suffering from cms3 colorectal cancer |
WO2018122249A1 (en) | 2016-12-28 | 2018-07-05 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for predicting the survival time of patients suffering from a microsatellite stable colorectal cancer |
WO2018146239A1 (en) | 2017-02-10 | 2018-08-16 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Biomarker for outcome in aml patients |
WO2018162404A1 (en) | 2017-03-06 | 2018-09-13 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Biomarker for outcome in aml patients |
WO2018172540A1 (en) | 2017-03-24 | 2018-09-27 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Method to predict the progression of alzheimer's disease |
EP3601613B1 (en) | 2017-03-29 | 2021-12-01 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for assessing pregnancy outcome |
WO2018189215A1 (en) | 2017-04-12 | 2018-10-18 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Method for predicting the survival time of a patient suffering from hepatocellular carcinoma |
WO2019038219A1 (en) | 2017-08-21 | 2019-02-28 | INSERM (Institut National de la Santé et de la Recherche Médicale) | New prognostic method of pancreatic cancer |
WO2019043138A1 (en) | 2017-09-01 | 2019-03-07 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Method for predicting the outcome of a cancer |
JP7038209B2 (en) | 2017-11-13 | 2022-03-17 | エフ.ホフマン-ラ ロシュ アーゲー | Equipment for sample analysis using epitaco electrophoresis |
JP7372927B6 (en) | 2018-02-12 | 2023-11-27 | ナノストリング テクノロジーズ,インコーポレイティド | Biomolecular probes and detection methods for detecting gene and protein expression |
WO2019207030A1 (en) | 2018-04-26 | 2019-10-31 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for predicting a response with an immune checkpoint inhibitor in a patient suffering from a lung cancer |
AU2019271028A1 (en) | 2018-05-14 | 2020-12-03 | Nanostring Technologies, Inc. | Chemical compositions and methods of using same |
WO2019229489A1 (en) | 2018-05-31 | 2019-12-05 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Use of mir-146a-5p and mir-186 as biomarkers of osteoarthritis |
US11460403B2 (en) | 2018-07-05 | 2022-10-04 | AhuraTech LLC | Electroluminescent methods and devices for characterization of biological specimens |
US11428656B2 (en) | 2018-07-05 | 2022-08-30 | AhuraTech LLC | Electroluminescent methods and system for real-time measurements of physical properties |
US11393387B2 (en) | 2018-07-05 | 2022-07-19 | AhuraTech LLC | Open-circuit electroluminescence |
CN109187484B (en) * | 2018-09-13 | 2020-12-04 | 广西师范大学 | Method for detecting biotin by using affinity reaction to regulate and control carbon dot catalysis SERS |
WO2020089432A1 (en) | 2018-11-02 | 2020-05-07 | INSERM (Institut National de la Santé et de la Recherche Médicale) | New prognostic method of pancreatic cancer |
WO2020089428A1 (en) | 2018-11-02 | 2020-05-07 | INSERM (Institut National de la Santé et de la Recherche Médicale) | New prognostic method of pancreatic cancer |
AU2020205150A1 (en) | 2019-01-03 | 2021-07-22 | Assistance Publique-Hôpitaux De Paris (Aphp) | Methods and pharmaceutical compositions for enhancing CD8+ T cell-dependent immune responses in subjects suffering from cancer |
EP3911669A1 (en) | 2019-01-16 | 2021-11-24 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Variants of erythroferrone and their use |
EP3924520A1 (en) | 2019-02-13 | 2021-12-22 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and compositions for selecting a cancer treatment in a subject suffering from cancer |
WO2020182932A1 (en) | 2019-03-13 | 2020-09-17 | INSERM (Institut National de la Santé et de la Recherche Médicale) | New gene signatures for predicting survival time in patients suffering from renal cell carcinoma |
WO2020193740A1 (en) | 2019-03-28 | 2020-10-01 | INSERM (Institut National de la Santé et de la Recherche Médicale) | New strategy for treating pancreatic cancer |
EP3947737A2 (en) | 2019-04-02 | 2022-02-09 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods of predicting and preventing cancer in patients having premalignant lesions |
WO2020212586A1 (en) | 2019-04-18 | 2020-10-22 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for the treatment and prognosis of cancer |
EP3959340A1 (en) | 2019-04-24 | 2022-03-02 | Institut National de la Santé et de la Recherche Médicale (INSERM) | Method for predicting the response of antipsychotic drugs |
WO2020229521A1 (en) | 2019-05-14 | 2020-11-19 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for inhibiting or reducing bacterial biofilms on a surface |
US20220325268A1 (en) | 2019-05-14 | 2022-10-13 | Roche Sequencing Solutions, Inc | Devices and methods for sample analysis |
WO2021001539A1 (en) | 2019-07-04 | 2021-01-07 | INSERM (Institut National de la Santé et de la Recherche Médicale) | New strategy to detect and treat eosinophilic fasciitis |
WO2021044012A1 (en) | 2019-09-05 | 2021-03-11 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Method of treatment and pronostic of acute myeloid leukemia |
WO2021063968A1 (en) | 2019-09-30 | 2021-04-08 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Method and composition for diagnosing chronic obstructive pulmonary disease |
EP4045686A1 (en) | 2019-10-17 | 2022-08-24 | Institut National de la Santé et de la Recherche Médicale (INSERM) | Methods for diagnosing nasal intestinal type adenocarcinomas |
CN112925005B (en) * | 2019-12-05 | 2023-09-08 | 中核四0四有限公司 | Method for measuring plutonium content of neptunium dioxide sample |
US20230113705A1 (en) | 2020-02-28 | 2023-04-13 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for diagnosing, prognosing and managing treatment of breast cancer |
WO2021186014A1 (en) | 2020-03-20 | 2021-09-23 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Method for predicting the survival time of a patient suffering from a cancer |
EP4165214A1 (en) | 2020-06-10 | 2023-04-19 | Institut National de la Santé et de la Recherche Médicale (INSERM) | Method for treating and prognosing cancer like glioblastoma |
WO2021255204A1 (en) | 2020-06-18 | 2021-12-23 | INSERM (Institut National de la Santé et de la Recherche Médicale) | New strategy for treating pancreatic cancer |
WO2022018163A1 (en) | 2020-07-22 | 2022-01-27 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Method for predicting survival time in patients suffering from cancer |
WO2022064049A1 (en) | 2020-09-28 | 2022-03-31 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Method for diagnosing brucella infection |
WO2022084327A1 (en) | 2020-10-20 | 2022-04-28 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Method for predicting the response to tnf inhibitors |
JP2023548421A (en) | 2020-11-06 | 2023-11-16 | インサーム(インスティテュ ナシオナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシェ メディカル) | Methods for diagnosing and treating polycystic ovarian syndrome (PCOS) |
WO2022136252A1 (en) | 2020-12-21 | 2022-06-30 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for prognosis the humoral response of a subject prior to vaccination |
WO2022135753A1 (en) | 2020-12-21 | 2022-06-30 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for prognosis the humoral response of a subject prior to vaccination |
WO2022152698A1 (en) | 2021-01-12 | 2022-07-21 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Use of npdk-d to evaluate cancer prognosis |
WO2022171611A1 (en) | 2021-02-09 | 2022-08-18 | INSERM (Institut National de la Santé et de la Recherche Médicale) | New method to pronostic lung cancer |
WO2022194949A1 (en) | 2021-03-17 | 2022-09-22 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Method for diagnosing pancreatic cancer |
WO2022207566A1 (en) | 2021-03-29 | 2022-10-06 | INSERM (Institut National de la Santé et de la Recherche Médicale) | New method to evaluate pancreatic cancer prognosis |
WO2022223791A1 (en) | 2021-04-23 | 2022-10-27 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and compositions for treating cell senescence accumulation related disease |
WO2023280790A1 (en) | 2021-07-05 | 2023-01-12 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Gene signatures for predicting survival time in patients suffering from renal cell carcinoma |
WO2023089159A1 (en) | 2021-11-22 | 2023-05-25 | INSERM (Institut National de la Santé et de la Recherche Médicale) | New strategy targeting stroma/tumor cell crosstalk to treat a cancer |
WO2023144303A1 (en) | 2022-01-31 | 2023-08-03 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Cd38 as a biomarker and biotarget in t-cell lymphomas |
WO2023152133A1 (en) | 2022-02-08 | 2023-08-17 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Method for diagnosing colorectal cancer |
WO2024061930A1 (en) | 2022-09-22 | 2024-03-28 | Institut National de la Santé et de la Recherche Médicale | New method to treat and diagnose peripheral t-cell lymphoma (ptcl) |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1998004740A1 (en) * | 1996-07-29 | 1998-02-05 | Nanosphere Llc | Nanoparticles having oligonucleotides attached thereto and uses therefor |
US5990479A (en) * | 1997-11-25 | 1999-11-23 | Regents Of The University Of California | Organo Luminescent semiconductor nanocrystal probes for biological applications and process for making and using such probes |
EP0990903A1 (en) * | 1998-09-18 | 2000-04-05 | Massachusetts Institute Of Technology | Biological applications of semiconductor nanocrystals |
Family Cites Families (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4868105A (en) * | 1985-12-11 | 1989-09-19 | Chiron Corporation | Solution phase nucleic acid sandwich assay |
JPH03279860A (en) * | 1990-03-29 | 1991-12-11 | Mitsui Petrochem Ind Ltd | Inspecting method and inspecting reagent |
US5665582A (en) * | 1990-10-29 | 1997-09-09 | Dekalb Genetics Corp. | Isolation of biological materials |
US5505928A (en) | 1991-11-22 | 1996-04-09 | The Regents Of University Of California | Preparation of III-V semiconductor nanocrystals |
US5674698A (en) * | 1992-09-14 | 1997-10-07 | Sri International | Up-converting reporters for biological and other assays using laser excitation techniques |
JP3410777B2 (en) * | 1993-09-13 | 2003-05-26 | 株式会社東芝 | Ultrafine inorganic phosphor-labeled specific binding substance and detection method using the same |
JP3517031B2 (en) * | 1995-06-09 | 2004-04-05 | 日清紡績株式会社 | Analytical methods for biologically active substances |
US5690807A (en) | 1995-08-03 | 1997-11-25 | Massachusetts Institute Of Technology | Method for producing semiconductor particles |
US5861279A (en) * | 1996-01-17 | 1999-01-19 | Schering Corporation | Baculovirus expression system for human interleukin 5 receptor and method of screening for interleukin 5 antagonists |
DE19627290A1 (en) * | 1996-07-06 | 1998-01-08 | Boehringer Mannheim Gmbh | Determination of analytes using two labels |
US5739001A (en) * | 1996-10-29 | 1998-04-14 | E. I. Du Pont De Nemours And Company | Solid phase cell-based assay |
JPH1151935A (en) * | 1997-08-06 | 1999-02-26 | Aisin Seiki Co Ltd | Simultaneous detection method for plural kinds of target molecules |
US6322901B1 (en) | 1997-11-13 | 2001-11-27 | Massachusetts Institute Of Technology | Highly luminescent color-selective nano-crystalline materials |
US6207392B1 (en) * | 1997-11-25 | 2001-03-27 | The Regents Of The University Of California | Semiconductor nanocrystal probes for biological applications and process for making and using such probes |
EP1113986A2 (en) | 1998-09-18 | 2001-07-11 | Massachusetts Institute Of Technology | Inventory control |
US6306610B1 (en) * | 1998-09-18 | 2001-10-23 | Massachusetts Institute Of Technology | Biological applications of quantum dots |
DE19905277A1 (en) * | 1999-02-09 | 2000-08-10 | Bayer Ag | Process for the preparation of 2-aminomethyl-1,5-pentanediamine |
US20010055764A1 (en) * | 1999-05-07 | 2001-12-27 | Empedocles Stephen A. | Microarray methods utilizing semiconductor nanocrystals |
DE60042738D1 (en) * | 1999-05-07 | 2009-09-24 | Life Technologies Corp | PROCESS FOR DETECTING ANALYTES USING SEMICONDUCTOR ANOCRYSTALLES |
-
2000
- 2000-05-05 DE DE60042738T patent/DE60042738D1/en not_active Expired - Lifetime
- 2000-05-05 US US09/566,014 patent/US6274323B1/en not_active Expired - Lifetime
- 2000-05-05 AT AT00928836T patent/ATE439452T1/en not_active IP Right Cessation
- 2000-05-05 EP EP00928836A patent/EP1179185B1/en not_active Expired - Lifetime
- 2000-05-05 AU AU47012/00A patent/AU4701200A/en not_active Abandoned
- 2000-05-05 CA CA002373146A patent/CA2373146A1/en not_active Abandoned
- 2000-05-05 WO PCT/US2000/012227 patent/WO2000068692A1/en active Application Filing
- 2000-05-05 JP JP2000616425A patent/JP2002544488A/en active Pending
-
2001
- 2001-06-21 US US09/887,914 patent/US6630307B2/en not_active Expired - Lifetime
-
2003
- 2003-07-30 US US10/631,573 patent/US20040166505A1/en not_active Abandoned
-
2008
- 2008-05-19 US US12/123,446 patent/US20090176221A1/en not_active Abandoned
-
2012
- 2012-04-09 US US13/442,717 patent/US20120252018A1/en not_active Abandoned
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1998004740A1 (en) * | 1996-07-29 | 1998-02-05 | Nanosphere Llc | Nanoparticles having oligonucleotides attached thereto and uses therefor |
US5990479A (en) * | 1997-11-25 | 1999-11-23 | Regents Of The University Of California | Organo Luminescent semiconductor nanocrystal probes for biological applications and process for making and using such probes |
EP0990903A1 (en) * | 1998-09-18 | 2000-04-05 | Massachusetts Institute Of Technology | Biological applications of semiconductor nanocrystals |
Non-Patent Citations (4)
Title |
---|
BRUCHEZ M JR ET AL: "Semiconductor nanocrystals as fluorescent biological labels", SCIENCE,US,AMERICAN ASSOCIATION FOR THE ADVANCEMENT OF SCIENCE,, vol. 281, no. 281, 25 September 1998 (1998-09-25), pages 2013 - 2016-2016, XP002125872, ISSN: 0036-8075 * |
CHAN WCW ET AL: "Quantum Dot bioconjugates for ultrasensitive nonisotopic detection", SCIENCE,US,AMERICAN ASSOCIATION FOR THE ADVANCEMENT OF SCIENCE,, vol. 281, no. 281, 25 September 1998 (1998-09-25), pages 2016 - 2018-2018, XP002125871, ISSN: 0036-8075 * |
DABBOUSI B O: "(CDSE)ZNS CORE-SHELL QUANTUM DOTS: SYNTHESIS AND CHARACTERIZATIONS OF A SIZE SERIES OF HIGHLY LUMINESCENT NANOCRYSTALLITES", JOURNAL OF PHYSICAL CHEMISTRY. B, MATERIALS, SURFACES, INTERFACES AND BIOPHYSICAL,US,WASHINGTON, DC, vol. 101, no. 46, 13 November 1997 (1997-11-13), pages 9463 - 9475, XP002095418, ISSN: 1089-5647 * |
LACOSTE T.D. ET AL.: "Super resolution molecualr ruler using single quantum dots", BIOPHYSICAL JOURNAL, vol. 78, January 2000 (2000-01-01), pages 402A, XP000933548 * |
Cited By (56)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9304084B2 (en) | 1998-09-24 | 2016-04-05 | Life Technologies Corporation | Spatial positioning of spectrally labeled beads |
US9046477B2 (en) | 1998-09-24 | 2015-06-02 | Life Technologies Corporation | Spatial positioning of spectrally labeled beads |
US9228948B2 (en) | 1998-09-24 | 2016-01-05 | Life Technologies Corporation | Spatial positioning of spectrally labeled beads |
US9297762B2 (en) | 1998-09-24 | 2016-03-29 | Life Technologies Corporation | Spatial positioning of spectrally labeled beads |
WO2001057522A2 (en) * | 2000-02-07 | 2001-08-09 | Quantum Dot Corporation | Immunochromatographic methods which employ semiconductor nanocrystals |
WO2001057522A3 (en) * | 2000-02-07 | 2002-02-14 | Quantum Dot Corp | Immunochromatographic methods which employ semiconductor nanocrystals |
EP1255866A4 (en) * | 2000-02-16 | 2004-12-22 | Quantum Dot Corp | Microarray methods utilizing semiconductor nanocrystals |
EP1255866A1 (en) * | 2000-02-16 | 2002-11-13 | Quantum Dot Corporation | Microarray methods utilizing semiconductor nanocrystals |
WO2001077391A1 (en) * | 2000-04-06 | 2001-10-18 | Quantum Dot Corporation | Spatial positioning of spectrally labeled beads |
JP2003531734A (en) * | 2000-04-06 | 2003-10-28 | クアンタム・ドット・コーポレーション | Discriminable spectral barcode method and system |
US7079241B2 (en) | 2000-04-06 | 2006-07-18 | Invitrogen Corp. | Spatial positioning of spectrally labeled beads |
US6759235B2 (en) | 2000-04-06 | 2004-07-06 | Quantum Dot Corporation | Two-dimensional spectral imaging system |
US7559481B2 (en) | 2000-04-06 | 2009-07-14 | Life Technologies Corporation | Differentiable spectral bar code methods and systems |
US8405828B2 (en) | 2000-04-06 | 2013-03-26 | Life Technologies Corporation | Spatial positioning of spectrally labeled beads |
WO2002043159A3 (en) * | 2000-10-19 | 2003-04-17 | Arch Dev Corp | Doped semiconductor nanocrystals |
WO2002043159A2 (en) * | 2000-10-19 | 2002-05-30 | Arch Development Corporation | Doped semiconductor nanocrystals |
WO2002099425A3 (en) * | 2001-06-06 | 2003-05-30 | Dynal Biotech Asa | Polymeric bead probe with nanocrystal, manufacture and use of the same |
WO2002099425A2 (en) * | 2001-06-06 | 2002-12-12 | Dynal Biotech Asa | Polymeric bead probe with nanocrystal, manufacture and use of the same |
EP1448800A4 (en) * | 2001-11-21 | 2007-05-16 | Applera Corp | Digital assay |
JP2005517900A (en) * | 2001-11-21 | 2005-06-16 | アプレラ コーポレイション | Digital assay |
EP1448800A2 (en) * | 2001-11-21 | 2004-08-25 | Applera Corporation | Digital assay |
EP2196544A1 (en) | 2001-11-21 | 2010-06-16 | Applied Biosystems, LLC | Kit for ligation detection assays using codeable labels |
JP2005513497A (en) * | 2002-01-03 | 2005-05-12 | カール ツァイス イエナ ゲゼルシャフト ミット ベシュレンクテル ハフツング | Method and / or apparatus for identification of fluorescent, luminescent and / or light-absorbing substances on and / or in a sample carrier |
WO2004008143A1 (en) * | 2002-07-12 | 2004-01-22 | Micronas Holding Gmbh | Method for determining the number of receptors on a carrier |
KR100999437B1 (en) * | 2002-09-06 | 2010-12-09 | 노바티스 백신즈 앤드 다이아그노스틱스 인코포레이티드 | Methods for verifying fluid movement |
JP2005538353A (en) * | 2002-09-06 | 2005-12-15 | カイロン コーポレイション | Method for verifying fluid movement |
US7361821B2 (en) | 2002-09-20 | 2008-04-22 | Intel Corporation | Controlled alignment of nanobarcodes encoding specific information for scanning probe microscopy (SPM) reading |
US7476786B2 (en) | 2002-09-20 | 2009-01-13 | Intel Corporation | Controlled alignment of nano-barcodes encoding specific information for scanning probe microscopy (SPM) reading |
US7531726B2 (en) | 2002-09-20 | 2009-05-12 | Intel Corporation | Controlled alignment of nanobarcodes encoding specific information for scanning probe microscopy (SPM) reading |
EP1546983A4 (en) * | 2002-09-20 | 2006-03-15 | Intel Corp | Controlled aligment of nano-barcodes encoding specific information for scanning probe microscopy (spm) reading |
EP1546983A2 (en) * | 2002-09-20 | 2005-06-29 | Intel Corporation | Controlled aligment of nano-barcodes encoding specific information for scanning probe microscopy (spm) reading |
US7705222B2 (en) | 2002-09-20 | 2010-04-27 | Intel Corporation | Controlled alignment of nano-barcodes encoding specific information for scanning probe microscopy (SPM) |
WO2004027095A1 (en) * | 2002-09-20 | 2004-04-01 | Intel Corporation | Controlled alignment of nanobarcodes encoding specific information for scanning probe microscopy (spm) reading |
US8088630B2 (en) | 2003-07-23 | 2012-01-03 | Ctl Analyzers, Llc | Nanoparticle and microparticle based detection of cellular products |
US9063145B2 (en) | 2003-07-23 | 2015-06-23 | Cellular Technology Limited | Multivalent opsonophagocytic assay using bead array and imaging |
WO2005012505A2 (en) * | 2003-07-23 | 2005-02-10 | Cellular Technology Ltd. | Nanoparticle and microparticle based detection of cellular products |
US7598093B2 (en) | 2003-07-23 | 2009-10-06 | Ctl Analyzers, Llc | Nanoparticle and microparticle based detection of cellular products |
WO2005012505A3 (en) * | 2003-07-23 | 2005-06-16 | Cellular Technology Ltd | Nanoparticle and microparticle based detection of cellular products |
WO2008036217A1 (en) * | 2006-09-20 | 2008-03-27 | Nellcor Puritan Bennett Llc | System and method for practicing spectrophotometry using light emitting nanostructure devices |
JP2010518862A (en) * | 2007-02-21 | 2010-06-03 | ライフ テクノロジーズ コーポレーション | Materials and methods for single molecule nucleic acid sequencing |
EP2126072A4 (en) * | 2007-02-21 | 2011-07-13 | Life Technologies Corp | Materials and methods for single molecule nucleic acid sequencing |
EP2126072A1 (en) * | 2007-02-21 | 2009-12-02 | Life Technologies Corporation | Materials and methods for single molecule nucleic acid sequencing |
US8110403B2 (en) | 2008-02-12 | 2012-02-07 | Fujifilm Corporation | Immunoassay method |
US10308983B2 (en) | 2011-02-04 | 2019-06-04 | The Trustees of The University of Pennsylvnia | Method for detecting chromosome structure and gene expression simultaneously in single cells |
CN105353131A (en) * | 2015-10-23 | 2016-02-24 | 山东大学 | Cytokine multiple detection method based on dual coding and monomolecular counting |
CN105353131B (en) * | 2015-10-23 | 2017-04-19 | 山东大学 | Cytokine multiple detection method based on dual coding and monomolecular counting |
WO2018213604A3 (en) * | 2017-05-18 | 2018-12-27 | Locus Agriculture Ip Company, Llc | Diagnostic assays for detecting, quantifying, and/or tracking microbes and other analytes |
CN113631912A (en) * | 2019-03-28 | 2021-11-09 | 阿兰蒂克微科学股份有限公司 | Bead-based sample analysis |
WO2020191480A1 (en) | 2019-03-28 | 2020-10-01 | Alentic Microscience Inc. | Bead-based analysis of a sample |
EP3948238A4 (en) * | 2019-03-28 | 2022-06-01 | Alentic Microscience Inc. | Bead-based analysis of a sample |
US11609233B2 (en) | 2019-03-28 | 2023-03-21 | Alentic Microscience Inc. | Indicator-based analysis of a sample |
CN113631912B (en) * | 2019-03-28 | 2023-07-18 | 阿兰蒂克微科学股份有限公司 | Bead-based sample analysis |
US11719700B2 (en) | 2019-03-28 | 2023-08-08 | Alentic Microscience Inc. | Upconversion for microscopy |
US11733239B2 (en) | 2019-03-28 | 2023-08-22 | Alentic Microscience Inc. | Bead-based analysis of a sample |
JP7450636B2 (en) | 2019-03-28 | 2024-03-15 | アレンティック マイクロサイエンス インコーポレイテッド | Bead-based analysis of samples |
US11692989B2 (en) | 2019-07-11 | 2023-07-04 | Locus Solutions Ipco, Llc | Use of soil and other environmental data to recommend customized agronomic programs |
Also Published As
Publication number | Publication date |
---|---|
US20120252018A1 (en) | 2012-10-04 |
ATE439452T1 (en) | 2009-08-15 |
DE60042738D1 (en) | 2009-09-24 |
US20040166505A1 (en) | 2004-08-26 |
JP2002544488A (en) | 2002-12-24 |
US20010034034A1 (en) | 2001-10-25 |
AU4701200A (en) | 2000-11-21 |
EP1179185A1 (en) | 2002-02-13 |
CA2373146A1 (en) | 2000-11-16 |
US6274323B1 (en) | 2001-08-14 |
US6630307B2 (en) | 2003-10-07 |
EP1179185B1 (en) | 2009-08-12 |
US20090176221A1 (en) | 2009-07-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US6274323B1 (en) | Method of detecting an analyte in a sample using semiconductor nanocrystals as a detectable label | |
JP4425470B2 (en) | Biological applications of semiconductor nanocrystals | |
EP0990903B1 (en) | Biological applications of semiconductor nanocrystals | |
US20010055764A1 (en) | Microarray methods utilizing semiconductor nanocrystals | |
US6306610B1 (en) | Biological applications of quantum dots | |
US6326144B1 (en) | Biological applications of quantum dots | |
US20040026684A1 (en) | Nanowire heterostructures for encoding information | |
KR100704011B1 (en) | Detection method for specific biomolecular interactions using FRET between metal nanoparticle and quantum dot | |
US6680211B2 (en) | Fluorescent nanocrystal-embedded microspheres for fluorescence analysis | |
US20060008921A1 (en) | Immunochromatographic methods for detecting an analyte in a sample which employ semiconductor nanocrystals as detectable labels | |
Baptista et al. | Nanoparticles in molecular diagnostics | |
US20070161043A1 (en) | Methods of Preparing Multicolor Quantum Dot Tagged Beads and Conjugates Thereof | |
US10184935B2 (en) | Quantum dot-based optical sensors for rapid detection and quantitative analysis of biomolecules and biological materials | |
CA2400379A1 (en) | Microarray methods utilizing semiconductor nanocrystals | |
US20060240227A1 (en) | Nanocrystal coated surfaces | |
WO2001089585A1 (en) | tLUORESCENT NANOCRYSTAL-LABELLED MICROSPHERES FOR FLUORESCENCE ANALYSES |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
ENP | Entry into the national phase |
Ref document number: 2373146 Country of ref document: CA Ref country code: CA Ref document number: 2373146 Kind code of ref document: A Format of ref document f/p: F |
|
ENP | Entry into the national phase |
Ref country code: JP Ref document number: 2000 616425 Kind code of ref document: A Format of ref document f/p: F |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2000928836 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 2000928836 Country of ref document: EP |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |